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Chapter 1
Rheumatoid arthritis (RA) is a chronic, inflammatory disease affecting mainly 
the joints. It is a heterogeneous disease with an unpredictable course which can 
vary from mild to very disabling. In the literature, RA is often subdivided into 
early and long-standing or established RA, though the boundaries between those 
are not clearly defined. Studies concerning early RA in the past have included 
patients with disease duration up to seven years. Since the recent introduction of 
the term ‘window of opportunity’ in the treatment of early RA, the upper limit 
of disease duration has been considerably reduced to as low as one year to even 6 
months after disease onset (1;2). In this thesis, we use the term established RA for 
patients who fulfil the 1987 American College of Rheumatology (ACR) criteria 
for RA (3), and whose disease duration is longer than one year.  
 Optimising the treatment of early RA has become a big challenge for 
rheumatologists, and several large trials have been conducted in order to find 
treatment strategies to control the disease process as early as possible, and to 
prevent joint damage and disability (4;5). 
 In 2007, the prevalence of RA in the Netherlands was much higher than its 
incidence, respectively 148.300 (95%CI 101.800 – 215.700) patients versus 15.800 
new patients per year (6). These numbers show that the majority of RA patients 
in the clinical practice have longer disease duration and consequently more 
chance to have joint damage and functional disability. For these patients, the 
management goals are to control disease activity, to prevent further joint damage, 
to alleviate pain, to maintain function for activities of daily living and work, and 
to optimize quality of life. Further important goals are the minimization of the 
toxicity of therapeutic interventions and the control or prevention of RA-related 
co-morbidities. 
 In recent years, several new treatment options, including the so-called biological 
response modifying drugs (biological agents) have become available which offer 
new therapeutic options for patients with established RA. Nonetheless, though 
large randomized controlled trials (RCTs) have been conducted to investigate the 
effectiveness of these new therapies, little is known about their effectiveness in 
daily clinical practice. Previous research showed for instance, that the effect of 
tumor necrosis factor-α (TNF) blocking therapy was less pronounced in clinical 
practice than in published RCTs. Moreover, only 21% to 79% of the patients from 
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daily practice fulfil the inclusion criteria for RCTs (7;8). For determining the 
effect of therapy in patients with established RA in daily clinical practice, results 
from observational studies can be a valuable addition to those from RCTs. 
Aim of this thesis
The aims of this thesis are to explore the long-term consequences of established 
RA and to investigate possible treatment strategies with biological agents in these 
patients using observational data. Such data may contribute to the management 
of established RA in daily clinical practice.       
Content of this thesis
Long-term consequences of established RA
Chapter 2 is a review of the literature on the clinical manifestations and long-
term consequences of established RA, the possible treatment strategies, the role 
of prognostic factors, and the possibilities to measure disease outcome in these 
patients. 
 The peripheral joints of hands and feet are characteristically affected and 
assessed in RA, but other joints such as those of the cervical spine may be 
involved as well. Cervical spine damage due to RA may cause severe disability due 
to myelopathy and even mortality due to brainstem and spinal cord compression 
(9) though is often asymptomatic (10;11). Besides, surgical interventions are 
common in patients with RA. Patients with instability of the cervical spine might 
be at risk for spinal cord compression due to manipulation of the cervical spine 
during intubation or surgery (12). It is therefore crucial to identify those patients 
who have an increased risk for such severe complications. Chapter 3 describes 
the prevalence of RA-related cervical spine damage among patients from the 
Nijmegen RA Inception Cohort (13) over a period of at least 6 up to 12 years. The 
study also describes the relation between cervical spine damage and other disease 
specific factors, such as disease activity, functionality, and peripheral erosive joint 
damage. 
Management of established RA
Despite the high response rates to TNF blocking therapy (14-16), a significant 
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Chapter 1
number of patients fails to respond to TNF blocking therapy or experiences 
adverse events (17-19). For those who fail to improve using the initial dosage of a 
given TNF blocking agent a dose increase might be beneficial. A dose increase can 
also result in more toxicity and higher treatment costs. In Chapter 4, we evaluated 
if dose increase is an appropriate option in patients who failed to respond to the 
initial dosage of TNF blocking therapy. To this aim we investigated the frequency 
and effectiveness of increasing the dose of three TNF blocking agents, infliximab, 
adalimumab and etanercept in daily clinical practice.
 After failure of the initial TNF blocking agent with or without dose increase, 
a next treatment option is to switch to a second TNF blocking agent. Although 
it could seem againts expectations, previous studies have shown that switch to a 
second TNF blocking agent can be beneficial in patients who failed the first (20-
28). This might be due to the fact that the TNF blocking agents currently most 
frequently used (infliximab, adalimumab and etanercept) differ in biochemical 
structures and properties. We hypothesized that if the reason for discontinuation 
of the first TNF blocking agent is related to the underlying mechanism for failure 
(e.g. genetic variation leading to nonresponse or antibody formation leading to 
loss of response) it might also influence the effect a second TNF blocking agent. 
This was investigated in daily clinical practice as described in Chapter 5.
 If a patient with established RA fails to two TNF blocking agent, then two 
possible treatment options are: switching to a third TNF blocking agent or 
switching to another biological agent with a different mechanism of action. Since 
there are no RCTs to support superiority of one of these options, this decision is 
still at the discretion of the treating rheumatologist. In Chapter 6, we compared the 
effectiveness of a third TNF blocking agent with that of rituximab – a monoclonal 
antibody directed against CD20 on B cells – after failure to two TNF blocking 
agents in daily clinical practice. 
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Management of established rheumatoid arthritis 
with an emphasis on pharmacotherapy
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Chapter 2
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease without 
an exact, known aetiology, mainly affecting the joints, but other organ systems can 
be involved as well. The joint involvement is characterized by symmetric synovitis 
and destruction of cartilage and/or bone (1). RA is a heterogeneous disease, 
affecting 1% of the adult population (2), with an unpredictable course, varying 
from a mild to a very severe disabling disease (3-5). RA generally leads to pain, 
fatigue, irreversible joint damage, disability, and impaired social functioning. RA 
may have a high bearing on quality of life and the patient’s life expectancy may 
also be reduced due to co-morbid conditions such as cardiovascular disease (6). 
RA is not curable and generally patients need life-long treatment with a variety 
of drugs supported by non-pharmacological interventions such as physical and 
occupational therapy.
 Nowadays, RA is treated as early as possible, sometimes even before the diagnosis 
of RA has been established (7). The ultimate goals in the management of early 
RA are complete suppression of the disease process, regaining full function and 
prevention of joint damage, with the aim of stopping the disease process before it 
completely evolves (8-11). 
 In established RA, the management goals are to keep the disease activity as low 
as possible and to prevent radiographic joint damage progression, with the aim of 
alleviating pain, maintaining function for activities of daily living and work, and 
optimizing quality of life. Other important goals in the management of established 
RA are to keep the toxicity of therapeutic interventions at acceptable levels and 
to control or prevent RA-related co-morbidities. It would be an advantage for 
the management of established RA if factors predicting the disease course and 
response to pharmacotherapy were available. 
 In this chapter the characteristic manifestations of established RA will 
be discussed first. Then, since pharmacotherapy is the cornerstone of the 
management of established RA, an overview on the role of treatment strategies 
in the individual patient in daily clinical practice will be given. Finally, the role 
of prognostic factors and the possibilities for measuring the disease outcomes of 
therapy will be discussed.
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Size of the problem and characteristic manifestations of established RA
Disease activity, joint damage, disability and quality of life
At a group level, disease activity improves under the influence of treatment in 
the early phase of RA, remaining stable thereafter (12). In the individual patient, 
the disease course can fluctuate more, with periods of high disease activity and 
even complete remission (13;14). However, low disease activity or even complete 
suppression of the disease process is only reached in a minority of patients with 
established RA and generally this situation does not last (13). Disease activity is a 
major predictor for joint damage and disability (12;14-16). A low level of disease 
activity over time is associated with a lower rate of radiographic joint damage 
progression, but fluctuations in disease activity may cause additional damage 
(17). 
 Joint damage already occurs early in the disease, as has been shown in an 
inception cohort study of patients with early RA in which 70% of patients already 
had some joint destruction after the first year (18). It appears that joint damage 
progresses more rapidly during the early years with a decrease later in the disease 
(4;12;18-21). However, a constant progression of joint damage over time has also 
been found in several studies (22-25). Between individual patients, huge variations 
in radiographic joint damage over time are seen and radiographic progression 
may even occur during disease remission (26). Prognostic factors associated with 
more severe radiographic joint damage are joint damage at baseline, rheumatoid 
factor positivity, anti-cyclic citrullinated peptide (anti-CCP) positivity, disease 
duration, patient global health assessment, C-reactive protein (CRP), and 
erythrocyte sedimentation rate (ESR) (27-30). 
 Loss of function may be the consequence of disease activity, pain, and joint 
damage in established RA (25;31;32). With increased disease duration, joint 
damage contributes more to disability than disease activity does, in contrast to 
early disease where loss of function is mainly the result of disease activity (12;25). 
 Apart from disease activity, pain and joint damage, fatigue is also an important 
symptom, with great influence on a patient’s life, which may be more prevalent 
than previously thought (33). 
 All of the problems described above may result in social impairment, inability 
to work, psychological problems, and a considerable reduction in quality of life.
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Mortality and co-morbidities
Numerous studies have demonstrated an excess mortality in patients with RA 
compared with the general population (34). This excess mortality rate has been 
estimated at approximately 25% (35;36), although conflicting results have been 
found (37). These conflicting data may be the result of differences in study methods 
and investigated populations. However, RA itself is seldom regarded as a cause of 
death (6;38). In one study only 5% of deaths in RA patients were attributed to the 
disease (6), while other studies have even found no deaths attributable to RA (38). 
Most deaths in RA are caused by co-morbidities (38;39); between 27 and 80% of 
patients with RA have a coexistent disease (39-42). Cardiovascular disease is the 
most important co-morbid cause of death in patients with RA, being reported in 
42% of RA patients (6), with systemic inflammation as the major cause for excess 
cardiovascular co-morbidity (43;44). Other cardiovascular risk factors are, for 
instance, dyslipidemias, homocysteinemia due to treatment with methotrexate 
(MTX) or sulphasalazine, hypertension, and renal disease (45). Disease duration 
has been associated with a higher risk for cardiovascular disease (46-48). 
 Other co-morbidities associated with RA as cause of death are infections (9%), 
renal disease (8%), pulmonary disease (7%), and gastrointestinal disease (4%) 
(6). These percentages are slightly higher than those in the general population. 
Some may be caused by the disease process itself, such as secondary amyloidosis 
and pulmonary disease. Others may be caused by toxicity of the pharmacological 
therapy, e.g. gastrointestinal disease due to the use of non-steroidal anti-
inflammatory drugs (NSAIDs) and corticosteroids. Although patients with RA 
have an increased incidence of lymphoproliferative malignancies, especially in 
patients with severe disease (49), a higher rate of mortality due to malignancies 
has not always been found (50;51).
 Overall, predictors for mortality in patients with RA are patient’s age, sex, 
disease duration, functional status, extra-articular manifestations e.g. vasculitis 
and pulmonary disease (43), and the presence of co-morbidities (39;52;53). 
Higher disease activity levels have also been associated with lower survival rates 
(36). 
The economic impact of RA
For society, RA constitutes a significant economic burden (54). The magnitude 
of the total costs for society are broadly comparable in industrialised countries, 
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although variations occur across countries, healthcare system organisations, and 
geographic locations, which can make generalization of the cost estimates to the 
wider RA population difficult (54-57). 
 The major cost driver for direct costs is inpatient care. However, the availability 
of very effective but costly treatments such as the biological response modifying 
drugs (biological agents) may lead to medication being the major cost driver. 
The indirect costs are mostly due to the number of days absent from work. As 
a result, the indirect costs in working-age patients due to work disability may be 
substantially higher than the direct costs (54). Functional disability is strongly 
correlated with the direct and indirect costs in RA (10;54;57) and disease duration 
may also influence the direct costs. This increase in costs with disease duration 
may be explained by higher costs for, among other things, hospitalization and 
orthopaedic surgery in patients with a longer disease duration (58). Treating 
patients adequately with intensive therapies, including biological agents and 
disease-modifying antirheumatic drugs (DMARD) combination therapy, has the 
potential to be cost saving, especially in the long-term by, for example, preventing 
orthopaedic surgery, hospitalization and work disability (57). In recent years, 
cost-effectiveness analyses have raised awareness by aiming to analyse whether 
the additional cost of new interventions, such as the biological agents, are justified 
given the additional benefits when compared with an alternative. Standardized 
methodologies for performing these economic evaluations are necessary to be 
able to generalize the outcomes (57).  
What can be done: the evidence for different interventions
Pharmacological management of established RA
Adequate pharmacological treatment of established RA includes DMARDs and/
or biological agents as single or combination therapy, if necessary combined 
with corticosteroids, NSAIDs and/or other analgesics such as acetominophen 
and opoids. Supporting drugs, such as folic acid and gastric and bone protecting 
agents, are added if indicated to prevent the side-effects of these treatments.
 DMARDs influence the inflammatory process and may slow down the progression 
of joint damage (28;59). Currently available DMARDs are hydroxychloroquine, 
sulfasalazine, MTX, azathioprine, leflunomide, d-penicillamine, intramuscular 
gold, cyclosporine and cyclophosphamide. In recent years, target-oriented agents, 
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so-called biological agents, have been developed, including monoclonal antibodies 
directed against e.g. tumor necrosis factor-α (TNF) (infliximab, etanercept, 
adalimumab, golimumab and cetrolizumab) (60-64), CTLA-4 (abatacept) (65) 
and CD20 on B cells (rituximab) (66). The TNF blocking agents are already widely 
used in clinical practice (67) and have proven to suppress inflammation and slow 
down radiographic joint damage progression (62;68;69). Corticosteroids, given 
orally, intra-articularly or intramuscularly, reduce inflammation rapidly and slow 
down radiographic joint damage progression (70). They are generally not used as 
a single treatment for chronic use because of potential serious side effects (71).
They may be used as a bolus treatment to suppress disease activity rapidly in case 
of a disease flare, in low doses in combination with DMARD treatment, and as 
bridge therapy in awaiting the effect of a newly started DMARD. 
DMARD combination strategies
Combining DMARDs has been proven to be more effective than single DMARD 
treatment in patients with early and established RA, although the risk of toxicity 
is slightly higher (72). Besides, combination DMARD strategies slow down 
radiographic joint damage progression more powerfully (11;73;74), probably 
reduce drug resistance, and, therefore, prolong drug survival compared with 
single DMARD therapy (75). 
 In early RA, intensive DMARD combination strategies are used to attain 
complete suppression of the disease process as soon as possible (11;76) and the 
step-down strategy is most often used. This strategy starts with a combination 
of DMARDs, tapering the most toxic drug first, while continuing the DMARD 
with the best efficacy/toxicity ratio for as long as is necessary. Patients with 
established RA have already been treated with single or combination DMARD 
therapy. Adjustment of DMARD therapy in these patients is indicated when the 
patient does not respond to the current therapy, has a suboptimal response or 
experiences a disease flare after an initially good response to a treatment strategy. 
The treatment strategy may be adjusted by adding a new DMARD or combination 
of DMARDs, or the patient may switch from the current therapy to another single 
DMARD or combination of DMARDs. 
DMARD combinations
MTX has been used most often in clinical trials and clinical practice as a so-called 
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‘anchor drug’ (77;78). The reasons are: MTX has been shown to have a good 
efficacy/toxicity ratio, has a longer drug survival than most other DMARDs, and is 
relatively cheap (78). The addition of any DMARD to MTX has proven to be more 
effective than continuing MTX as single DMARD therapy in cases of treatment 
failure (72). In particular, MTX combined with TNF blocking agents and MTX 
combined with sulphasalazine and/or hydroxychloroquine have shown to have 
good efficacy/toxicity ratios (72). Other DMARD combinations, including MTX 
with leflunomide, cyclosporine and intramuscular gold have also been shown to 
be more effective than single DMARD therapy with these drugs (79-81). 
 At present, little evidence is available that supports combining traditional 
DMARDs other than MTX. Studies have been published combining e.g. 
sulfasalazine with leflunomide (82) and cyclosprine with chloroquine (83). 
However, these studies were not conclusive, particularly due to small patient 
numbers.
 Studies comparing different DMARD combinations or strategies are scarce. The 
BeSt study compared sequential substitution monotherapy, initial combination 
therapy with a short course of high dose prednisone and initial combination 
therapy with the TNF blocking agent infliximab. The results showed that initial 
combination therapy including either prednisone or infliximab resulted in earlier 
functional improvement and less radiographic damage after 1 year than the other 
two groups (11). This study was performed in patients with early RA (a disease 
duration of less than 2 years). Studies comparing different DMARD combinations 
or strategies in patients with established RA are not yet available.   
 The choice of combination DMARD strategy in the individual patient in daily 
clinical practice is largely empirical and depends mostly on the efficacy/toxicity 
ratios of the DMARDs involved. However, MTX has been shown to be effective in 
combination DMARD strategies, and may be used as the DMARD of first choice 
in the majority of patients with RA (77). 
 The introduction of new drugs, like the biological agents, has expanded the 
possibilities of combination therapy. Combining traditional DMARDs other than 
MTX, may further increase the possibilities. 
Biological response modifying drugs
If therapy with traditional DMARDs fails, a possible treatment option is to switch 
to or add a biological agent. According to the Dutch criteria for reimbursement, 
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RA patients may start a TNF blocking agent if they have moderate to high disease 
activity (DAS28 ≥ 3.2) and failure of at least 2 DMARDs including optimal 
doses of MTX (25 mg/week with folic acid supplement). At this moment, five 
TNF blocking agents have become available in daily clinical practice in the 
Netherlands, of which infliximab, adalimamab and etanercept have been already 
widely used over the last decade. Each of the TNF blocking agents has been 
proven to be efficacious in the treatment of RA, with response rates up to 70% 
in the active treatment groups of randomized controlled trials (RCTs), and slow 
down radiographic joint damage progression (60-64;69;84). As far as efficacy is 
concerned in patients with active disease, infliximab, adalimumab and etanercept 
in combination with MTX have not been proven to be superior above each other 
(85). Switching from one TNF blocking agent to another seems to be reasonable 
in patients with insufficient response to the first agent (86). 
 More target-oriented biological agents have been recently developed, including 
monoclonal antibodies directed against CTLA-4 (abatacept) (65), interleukin-6 
receptor (tocilizumab) (87), and CD20 on B-cells (rituximab) (66). All have been 
proven to be efficacious in RCTs. The introduction of these new drugs has further 
expanded the possibilities in the pharmacological treatment of established RA. 
Non-pharmacological treatment in established RA
Although pharmacological treatment is the cornerstone in the management 
of established RA, various health care professionals with different areas of 
expertise, collaborating in a multidisciplinary team, are necessary for the optimal 
management of patients with established RA due to the complexity of the 
problems resulting from the disease. Such a team would include, for instance, an 
orthopaedic surgeon, a specially trained nurse, a social worker, a psychologist, a 
physical therapist, an occupational therapist, and a rheumatologist as coordinator. 
Each health care professional has a specific role in the management of a patient 
with established RA, e.g. pain and loss of function due to the destruction of a joint 
may benefit from surgical intervention (88). Specially trained nurses may provide 
information about the disease and its consequences. Psychological interventions, 
such as relaxation strategies and cognitive behavioural interventions, may be 
used as adjunctive therapy in patients with RA (89;90). Lifestyle interventions, 
such as exercise, smoking cessation, and weight reduction, may have an impact 
on the prevention or reduction of co-morbidities (45). Specific physiotherapy 
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programmes have been developed for patients with RA to enhance mobility by 
improving flexibility, strength and endurance in performing activities (91) and an 
occupational therapist may be involved in maintaining function, independence 
and ability to complete activities of daily living, by giving support for joint 
protection and proper ergonomics at home and work.
How to identify those who will benefit from interventions: prognostic 
factors in the management of established RA
In early arthritis and RA, prognostic factors are used for diagnosis and to predict 
the course of the disease, in order to define an adequate management plan to 
suppress the disease process as early as possible (7). In established RA, a diagnosis 
has already been reached and joint damage may be present. However, prognostic 
factors may still be used in predicting disease outcome, such as predicting which 
patient will have more rapid radiographic joint damage progression and a more 
disabling disease course. Those patients with an expected severe disease course may 
be treated more intensively, which is consequently more expensive and more toxic. 
 Another role for prognostic factors in established RA may be predicting the 
outcome of pharmacological management, such as which patient will benefit 
from which therapy and predicting the toxicities of different treatment strategies. 
In one study, patients with a longer disease duration did not respond to traditional 
DMARD treatment as well as patients with early disease (92). However, others 
have found that a longer disease duration does not appear to increase the risk 
of DMARD discontinuation (93). Other factors associated with the response 
to treatment with DMARDs and TNF blocking agents were female sex, prior 
DMARD use and, in particular, failure of MTX treatment, disease activity and 
disability (92-94). 
 In recent years, genetic markers predicting response to treatment have gained 
interest, because of the heterogeneous response to treatment of patients with RA. 
Genetic polymorphisms may influence the balance of pro- and anti-inflammatory 
cytokines. Therefore, a better understanding of these genetic factors may improve 
the clinical response to treatment (95;96). 
 At present, no single prognostic factor is able to predict patients with a poor 
prognosis. In the future, to predict the disease course and response to therapy, the 
emphasis will be on combining several prognostic markers. 
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How to measure the outcome of treatment strategies in patients with 
established RA
In order to evaluate, in daily clinical practice, whether the goals of pharmacological 
management in a patient with established have been reached, the patient may 
be closely monitored using frequent standardized assessments, reflecting the 
disease course to obtain a good picture of the response to treatment. Systematic 
monitoring of the disease activity in RA may lead to more changes in DMARD 
treatment, resulting in a larger number of patients with low disease activity 
(97;98). 
 Variables reflecting the disease course can be divided into process and outcome 
variables (99-101). Process variables are, e.g. tender and swollen joint counts, ESR 
and CRP. Outcome variables are disease aspects or consequences, which develop 
over the course of RA. These variables are a summation of past processes, e.g. joint 
damage, loss of function, psychological, social and economical consequences, 
toxicity, co-morbidities, and ultimately death. 
 Before treatment starts, baseline information is needed. This information 
should include disease activity, functional status, mechanical joint problems, 
presence of extra-articular disease, joint damage, and co-morbidities (102;103). 
Subsequently, follow-up data about the disease course using a standardized 
protocol is necessary. Disease activity, a process variable, should be assessed at 
frequent intervals over time, e.g. every 3 months. Outcome variables, such as 
disability and radiographic joint damage, must be measured regularly to assess 
the rate of change or progression. These measurements show less fluctuation and 
may be performed less often, for example every 6-12 months. Extra-articular 
manifestations and major co-morbidities have to be evaluated at regular time 
intervals, e.g. at every visit to the rheumatologist. 
 The instruments used for evaluation of RA in clinical practice will be discussed 
below (and see Table 1).
Disease activity
The disease activity may be assessed by joint counts, markers of inflammation 
such as ESR and CRP level, and by the visual analogue scale (VAS) pain and VAS 
global disease activity. Several scoring methods combining these assessments 
have been developed for overall disease activity. In clinical practice, a scoring 
method for disease activity should measure the current disease activity, it should 
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be sensitive to change preferably using a continuous scale and it should be well 
validated. Table 1 shows the methods most often used in clinical practice. All have 
been well validated and have a good sensitivity to change.  
 Response criteria, such as the American College of Rheumatology criteria 
for 20% clinical improvement (ACR20) and the European League Against 
Rheumatism response criteria (EULAR criteria) (104;105), have not been included 
in Table 1. These criteria emphasize change in disease state. Therefore, they do not 
allow the measurement of actual disease activity and do not enable comparison 
between absolute patient’s responses. However, these response criteria could be 
used to compare a patient’s response with the data from RCTs.
Disability
Questionnaires are the most commonly used instruments for measuring 
disability. Some health status questionnaires are available specifically for arthritis, 
such as the arthritis impact measurement scales (AIMS), the health assessment 
questionnaire (HAQ), and the McMaster Toronto Arthritis Patient Preference 
Disability Questionnaire (MACTAR) (Table 1) (106-110).
 All of the questionnaires mentioned above have been demonstrated to be 
sensitive in RA trials. However, in clinical practice the HAQ may be most useful, 
because this questionnaire takes little time to complete (111) and it is widely used 
in RCTs enabling a comparison of clinical patients with data from such trials.
Joint damage
Conventional postero-anterior radiographs of the hands and feet are widely 
used to evaluate joint damage progression in patients with RA. Magnetic 
resonance imaging (MRI) and ultrasonography (US) can also be used for this 
purpose. Besides, MRI and US have been demonstrated to be more sensitive than 
conventional radiography in detecting small erosions and soft tissue changes 
such as synovitis and tenosynovitis. MRI is especially sensitive in detecting early 
pathology and change. US has been less validated than MRI, but available data 
suggest that US offers comparable information to MRI on both inflammatory and 
destructive changes in RA finger and toe joints (112). However, MRI is expensive 
and US and MRI are unable to show multiple joints at the same time without 
being very time consuming. Therefore, the role of MRI and US in patients with 
established RA in daily clinical practice remains to be evaluated and conventional 
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postero-anterior radiographs of the hands and feet are still used most often. 
 Several methods have been developed for obtaining a radiographic score of 
erosions and/or joint space narrowing. The two most often validated scoring 
methods are the methods developed by Sharp et al. and Larsen (113;114). These 
scoring methods have been modified several times, for instance the Sharp/van der 
Heijde score (115), the Larsen/Rau score (116), and the simple erosion narrowing 
score (SENS) (117). A comparison of these five scoring methods in patients with 
early RA, using postero-anterior radiographs of  the hands, showed high intra- 
and interobserver reliability for each method with similar sensitivity to change, 
Table 1: Process and outcome variables and their assessments
Variable Assessment
Disease activity DAS (119)
 DAS28 (120)
 SDAI (121)
 RADAI (122)
Disability AIMS (106)
 HAQ (108;109)
 MACTAR (110)
Joint damage Conventional radiographs of hands and feet: 
 - Sharp et al. (113)
 - Sharp/van der Heijde (115)
 - SENS (117)
 - Larsen (114)
 - Larsen/Rau (116)
 - Ratingen (123)
 MRI (124)
 Ultrasonography (124)
DAS, Disease Activity Score; SDAI, simplified disease activity index; RADAI, rheumatoid arthritis dis-
ease activity index; AIMS, arthritis index measurement scales; HAQ, health assessment questionnaire; 
MACTAR, McMaster Toronto Arhtritis Patient Preference Disability Questionnaire; SENS, simple narrow-
ing score; MRI, magnetic resonance imaging.
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although the interobserver reproducibility decreased in patients with more severe 
joint damage (118). 
 
Conclusion
Pharmacological therapy is the cornerstone in the management of established 
RA. However, it is difficult to predict which patients will respond to DMARD 
therapy. Patients not responding to initial DMARD therapy are candidates for 
therapy change including combination strategies. Generally, MTX is regarded as 
the DMARD of first choice and MTX is most often used in combination strategies. 
Combination DMARD therapy has proven to be effective in suppressing disease 
activity and slowing down radiographic joint damage progression. Combinations 
with MTX and TNF blocking agents and MTX with sulphasalzine and/or 
hydroxychloroquine have shown good efficacy/toxicity ratios. Other DMARD 
combinations with MTX, including leflunomide, cyclosporine and intramuscular 
gold, have also shown to be effective in clinical trials. The introduction of 
biological agents has further expanded the treatment options in established RA. 
 For optimal treatment in clinical practice, a longitudinal management plan 
should be defined for each individual patient with established RA, including the 
goals of treatment and the pharmacological and non-pharmacological therapies 
necessary to reach these goals. This management plan may be adjusted during 
patient follow-up using information from measurements of disease activity, 
disability and joint damage.  
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Long-term follow-up of the cervical spine 
with conventional radiographs in patients 
with rheumatoid arthritis
doc.blom.indd   41 27-11-12   15:01
42
Marlies Blom1
Marjonne CW Creemers2
Wietske Kievit1
J Albert M Lemmens3
Piet LCM van Riel1
Departments of Rheumatology, 1Radboud University Nijmegen Medical Centre, Nijmegen, 
2Jeroen Bosch Hospital, ‘s Hertogenbosch. 
3Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen. 
Accepted for publication in Scan J Rheumatol, November 2012
doc.blom.indd   42 27-11-12   15:01
43
Chapter 3
Abstract
Objective
To investigate the prevalence of cervical spine damage due to rheumatoid arthritis 
(RA) on the long-term and to investigate which disease specific factors are related 
to this damage. 
Methods
Patients with early RA from the Nijmegen Inception cohort with at least 6 up to 12 
years of follow-up were included. Conventional radiographs of the cervical spine 
were obtained at baseline, 3, 6, 9, and 12 years and scored for erosions of C1 and 
C2, anterior atlantoaxial subluxation (AAS) and atlantoaxial impaction (AAI). 
Disease specific factors, such as disease activity, functionality, and peripheral 
joint damage at baseline, 3, 6 and 9 years were compared between patients with or 
without cervical spine damage at 9 years.
Results
A total of 196 patients were included of whom 134 had radiographs at 9 years. 
Cervical spine damage was present in 16% (22/134) of the patients at 9 years. 
During the total 12 years follow-up, AAS and erosions of C2 were most frequently 
observed. Erosions of C1 and AAI were very rare. Patients with cervical spine 
damage at 9 years had a higher number of erosions of the peripheral joints and 
failed more DMARDs at 3, 6 and 9 years. Patients without peripheral erosive 
disease at 3 years were unlikely to develop cervical spine damage within 9 years 
of disease duration. 
Conclusion
The prevalence of cervical spine damage due to RA was 16% at 9 years. Patients 
without peripheral erosive disease at 3 years were unlikely to develop cervical 
spine damage at 9 years. 
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Introduction
The cervical spine can be affected in rheumatoid arthritis (RA) with identical 
pathogenesis as the peripheral joints: inflammation of synovium and pannus 
formation lead to destruction of ligaments, cartilage, and bone. Examples of 
cervical spine damage due to RA are anterior atlantoaxial subluxation (AAS) and 
atlantoaxial impaction (AAI), also known as vertical atlantoaxial subluxation 
(1). 
 Cervical spine damage due to RA may cause pain and neurological symptoms 
due to myelopathy, and even sudden death caused by brainstem and spinal cord 
compression (1). However, these severe clinical manifestations are often not 
preceded by any related clinical symptoms (2;3). Besides, surgical procedures, in 
particular orthopedic surgery, are common in patients with RA. Patients with 
instability of the cervical spine may be at risk for spinal cord compression due 
to manipulation of the neck during intubation for general anaesthesia (4). It is 
therefore important to recognize those patients who have an increased risk of 
complications in order to prevent severe disability and mortality. 
 Conventional radiographs are frequently used to evaluate cervical spine 
damage in patients with RA. Cervical spine damage due to RA has been observed 
in a wide range from 17% up to 86% of patients with RA (5;6). The width of this 
range might result from a combination of factors such as the disease duration and 
disease severity of the population studied, the cervical spine damage investigated, 
and the assessments used to evaluate this damage. For example, more than 
seven possible assessments for evaluating AAI have been developed, some for 
diagnostic purpose, and others for longitudinal follow-up, but most of these 
assessments are not properly validated (7-12). Differences in study design are an 
additional explanation. Most studies investigating large patient populations are 
cross-sectional (5;13) or short-term prospective (14;15). Only a few long-term 
prospective studies are available with the longest mean follow-up time of 10.2 
years (range 5-20 years) and a maximum of 161 patients (16;17). 
 Several studies have been conducted to identify those patients at risk for 
cervical spine damage due to RA. Peripheral progressive erosive disease has 
been associated with a higher risk for AAS (18). Other possible predictive 
factors are acute phase reactants, including C-reactive protein (CRP) levels 
and the erythrocyte sedimentation rate (ESR), tender and swollen joint counts, 
disease duration, patient characteristics like age and gender, use of systemic 
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corticosteroids, and biomarkers like rheumatoid factor (RF) (14;19;20). Active 
and early treatment with disease-modifying antirheumatic drugs (DMARDs) 
has been shown to prevent the development of cervical spine damage due to RA 
(21). Despite the identification of these predictive factors, there are no guidelines 
whether radiographs of the cervical spine should be performed on a regular base 
or prior to anaesthesia. 
 In this descriptive study, we investigated the prevalence of cervical spine 
damage due to RA over a period of at least 6 up to 12 years in a large long-term 
observational cohort study including patients with early RA, the Nijmegen 
Inception Cohort (22). In addition, the relation of cervical spine damage to other 
disease specific factors, such as disease activity, functionality, and peripheral 
erosive joint damage was investigated. These data may be used to identify those 
patients at risk for cervical spine damage due to RA and to formulate guidelines 
for screening of cervical spine damage in daily practice.
Methods
Patients
All patients with RA who started in the Nijmegen Inception cohort (22) between 
January 1985 and January 1996 with at least 6 years follow-up at January 2002 were 
included in this study. The Nijmegen Inception cohort is a long term observational 
study of the Radboud University Nijmegen Medical Centre (RUNMC), including 
patients with RA according to the 1958 (later 1987) American College of 
Rheumatology criteria for RA (23), who have a maximum disease duration of 
one year, and who have received no prior treatment with DMARDs and systemic 
corticosteroids. According to the protocol, corticosteroid treatment ≤ 2 weeks 
and intramuscular corticosteroid injections ≤ 4 times prior to inclusion were 
permitted. Drug treatment decisions were made by the attending rheumatologist 
according to daily clinical practice standards. DMARDs were prescribed usually 
within the first months of disease onset. Initially the DMARD of first choice 
was sulfazalasine, later patients started with methotrexate as the first DMARD 
(22). The treatment goal was a Disease Activity Score in 28 joints (DAS28) < 3.2. 
DMARDs could be switched or added if necessary to reach this goal.
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Assessments
At inclusion, patient characteristics were recorded including date of birth, sex, 
date of diagnosis, and RF status. A trained study nurse assessed patients at 
baseline and every 3 months thereafter, performing tender and swollen joint 
counts (TJC and SJC), ESR, CRP level, and the visual analogue scale for general 
health (VASGH). The DAS28 was calculated to evaluate disease activity using the 
original formula (24). Functional disability was assessed by the Health Assessment 
Questionnaire (HAQ) every 6 months (25;26). Start and stop dates regarding RA 
treatment, including traditional DMARDs, biological agents and corticosteroids, 
doses of these agents, and reasons for changes or discontinuation were registered. 
Conventional posterior-anterior radiographs of the hands and feet were taken 
at inclusion, yearly for the first 3 years, and every 3 years thereafter. Erosion 
scores for the hands and feet were obtained using the Ratingen joint score by four 
trained and calibrated observers in chronological order (27;28). Conventional 
radiographs of the cervical spine in neutral lateral view and in flexion and 
extension were obtained at baseline and every 3 years thereafter. All radiographs 
of the cervical spine were made in lateral direction in upright position while the 
patient was either standing or sitting. The Focus-Film distance was standardized 
to 1.10 meter and automated settings were used to set the kV and Amp values. 
All radiographs were made with Siemens apparatus but on various machines. The 
dynamic lateral view were made without intervention from the radiographer. The 
patient was asked to flex and extend the head as good as was achievable. In all 
lateral views the focus was pinpointed at the cervical spine position on the level 
of the mandibular angle. 
Validation of selected scoring methods used to score cervical spine damage
First, a literature search was performed to identify cervical spine damage caused 
by RA and methods available to score this damage were selected. The results of this 
literature search were discussed by a panel of experts, including two experienced 
rheumatologists (MC and PvR), a radiologist specialized in RA (JL), and the 
investigator (MB) (face and content validity). The cervical spine damage resulting 
from RA identified was: erosions of C1, erosions of C2, atlantoaxial subluxations 
(AAS), and atlantoaxial impaction (AAI). Table 1 shows the scoring methods 
chosen from the literature. 
 Two observers (MC and MB) were trained and calibrated in using the chosen 
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scoring methods by a radiologist (JL) by using conventional radiographs of the 
cervical spine of patients with RA from the department of Rheumatology of the 
RUNMC who were not included in the Nijmegen Inception cohort. Agreements 
which were made included that all measurements should be performed in half 
millimeters and that in case of doubt the lower score was taken. 
 To determine the intraobserver and interobserver agreement of the chosen 
scoring methods, radiographs of the cervical spine of 55 patients with RA were 
randomly selected from the Nijmegen Inception cohort. Of these patients, 15 
sets of radiographs for each of the following time intervals were selected: 0-3 
years, 3-6 years, and 6-9 years. A number of 10 pairs of radiographs were selected 
for time interval 9-12 years. Each set of radiographs was scored twice in paired 
and chronological order by the two observers with a time interval of 4 weeks. 
Observers were blinded for the patient, for their own, and each others’ scores. The 
observers recorded the time needed to score a single set of radiographs. 
 The intraobserver and interobserver agreement of the developed scoring method 
were analysed by calculation of the intraclass correlation coefficient (ICC) for 
continuous data (29) and the Cohen’s kappa for dichotomous or categorical data. 
Due to dependency of the Cohen’s kappa for prevalence the Cohen’s kappa was 
adjusted for bias and prevalence (30). A good intraobserver and interobserver 
agreement was found for scoring AAS (0.73-0.96 and 0.58-0.92) and for scoring 
AAI using the method by McRae (7) (0.86-0.97 and 0.57-0.72). A moderate to 
good intraobserver and interobserver agreement was found for scoring erosions of 
C2 (0.37-0.83 and 0.52-0.77). Erosions of C1 were not observed in the selection of 
radiographs and AAI scored by using the method of Clark (9) was rare, therefore 
no intraobserver or interobserver agreement could be determined. Nevertheless, 
63 to 73% of the Clark scores were similar between the two observers.  
Determining the prevalence of cervical spine damage in the cohort
After the selection of the scoring methods for cervical spine damage due to RA, all 
radiographs of the included patients in this study were evaluated by one observer 
(MB) in chronological order. In case of doubt, expert opinion was asked from 
the second trained observer (MC) and the radiologist (JL). During collection of 
the radiographs for this study we were confronted with the fact that the protocol 
was not accurately followed in practice. As a result, a high number of radiographs 
were missing. Besides, initially the protocol prescribed to perform radiographs 
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of the cervical spine at baseline. However, about 5 years after start of the study 
the idea raised that cervical spine damage due to RA was not ready present at 
baseline. For this reason only a few baseline radiographs of the cervical spine 
were taken between 1990 and 1994. From 1994 the study design was followed 
more strictly again. Due to the high number of missing radiographs we were not 
able to investigate the change in time course of cervical spine damage due to RA 
as we initially planned for. For this reason the prevalence of cervical spine damage 
is presented as percentages at baseline, 3, 6, 9, and 12 years. 
Table 1: Scoring methods used to score cervical spine changes resulting from RA
Level Cervical spine change Assessment Radiograph Abnormal
C1	 Erosion	 Posterior	side	of		 Neutral	 ≥	mild	 		 	
	 	 anterior	bow:	absent,
	 	 mild,	moderate,	severe.
C1-C2	 Anterior	atlantoaxial	 Distance	in	mm	 Flexion	and	 >	3	mm	(3)
	 subluxation	(AAS)	 between	posterior	 extension	 Stable	if	difference
	 	 aspect	of	the	anterior	 	 between	flexion	and
	 	 bow	of	C1	and	the	 	 extension	≤2	mm		
	 	 of	C2	in	flexion.	 	 and	anterior	aspect	
	 	 	 	 extension	(49)	 	
	 Vertical	atlantoaxial		 1.	Adjusted	Clark-score:		 Neutral	 1.	Clark-score	>II.
	 subluxation	(VAS)	 C2	is	divided	in	6	equal		 	 2.	if	the	top	of	C2	is
	 	 parts	(I-VI).	The	height		 	 above	the	line.
	 	 of	the	middle	of	C1	
	 	 determines	the	score	(9)
	 	 2.	McRae:	distance	
	 	 (in	mm)	of	the	top	of	
	 	 C2	from	the	line	drawn	
	 	 between	the	anterior	
	 	 (middle	clivus)	and	
	 	 posterior	(lower	border	
	 	 os	occiput)	side	of	the	
	 	 foramen	magnum	(7)
C2	 Erosion	 Erosions	are		 Neutral	 Present
	 	 scored	as	absent	or	
	 	 present.
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 In order to determine possible disease specific factors associated with the 
development of cervical spine damage due to RA, the patients of whom radiographs 
were available at 9 years were divided into two groups: patients with cervical 
spine damage due to RA at 9 years (erosions of C1, of C2, AAS and/or AAI) and 
patients without any cervical spine damage. The following factors were compared 
between the two groups: age, sex, RF status, disease activity, and functionality 
at baseline; and disease activity, functionality, total erosion score for hands and 
feet, and number of previous antirheumatic medication (including DMARDs and 
biological agents) at 3, 6 and 9 years. Dependent of the distribution, the unpaired 
Student’s t test or the nonparametric Mann-Whithney U test for continuous data 
or the Pearson’s chi-squared test for categorical data were applied for comparison 
between groups. P-values of < 0.05 were considered significant. Analyses were 
performed using SPSS version 17.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Patient characteristics at baseline 
In total, 245 patients had at least 6 years of follow-up before January 2002. In 196 
of these patients, radiographs were available from at least two time points. At 
baseline, the mean age at diagnosis was 51.6 (SD 13.7) years, 64% (126/196) was 
female, 78% (152/196) was RF positive, the mean DAS28 was 5.45 (SD 1.38), the 
mean HAQ was 0.74 (SD 0.6, n = 127), and the median number of erosions of hands 
and feet was 1 (interquartile range [IQR] 3, n = 168). The longest mean follow-
up period of these patients was 11.6 years (IQR 5.33 years). Of the remaining 
49 patients, 36 had only one radiograph taken during this follow-up period and 
in 13 patients radiographs of the cervical spine were completely missing. The 
characteristics of these patients did not differ from the other patients, except that 
they were somewhat older (58.7 years [SD 14.0], P = 0.002). Of the 196 patients, 
60 (31%) had radiographs at baseline, 66 (34%) at 3 years, 180 (92%) at 6 years, 
134 (68%) at 9 years, and 78 (40%) at 12 years.
Prevalence of cervical spine damage
Table 2 shows the prevalences of cervical spine damage due to RA in our cohort of 
patients at baseline, 3, 6, 9 and 12 years of follow-up. Erosions of C1 were very rare. 
Only four patients showed erosions of C1 during the total study period. Erosions 
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of C2 were more frequently observed and its prevalence increased over time. The 
tip of the odontoid was almost completely vanished  in 4 patients during the total 
study period. 
 AAS was not observed at baseline, but the prevalence increased slowly over the 
following years. Of the total of 18 patients with AAS somewhere during the total 
study period of 12 years, only 6 showed a marked progression of at least 2 mm. Of 
the patients with AAS, the mean AAS was 5.8 mm (SD 1.9) at 3 years (n = 3), 6.5 
mm (SD 3.2) at 6 years (n = 10), 5.1 mm (SD 1.8) at 9 years (n = 9), and 5.7 mm 
(SD 1.8) at 12 years (n = 6). AAS can be characterized as stable and instable (as 
described in Table 1). AAS was instable in all 3 patients at 3 years, 6 of 10 patients 
at 6 years, 7 of 9 patients at 9 years, and 3 of 6 patients at 12 years.
 According to the classification of Clark (9) for AAI, 43.4%-50% of the patients 
scored a category II at any time point during the 12 years of follow-up. Only 2 
patients had a Clark category III, indicative for a AAI, during the total study period. 
If AAI was measured by the McRae score (7), no AAI was identified defined as 
protrusion of the tip of the odontoid process above the McRae line. However, in 
one of the patients with a AAI according to Clark the tip of the odontoid process 
just reached the McRae line at 12 years. In the other patient with Clark category 
III, the tip of the odontoid process was 4 and 4.5 mm under the McRae line at 6 
and 9 years, respectively. This was considerably lower than the means (± SD) of the 
total group:  12.7 (SD 3.5) mm at baseline, 12.2 (SD 2.8) mm at 3 years, 12.5 (SD 
3.1) mm at 6 years, 12.6 (SD 3.2) mm at 9 years, and 12.7 (SD 3.4) mm at 12 years. 
 Of the total of 245 patients in our study, only 2 patients received orthopaedic 
surgery of the cervical spine, both a ventral spondylodesis of C1 and C2. Patient 
A had the operation 13 years after disease onset because of an instable AAS of 20 
mm in flexion. This patient complained of neck pain, subjective mild weakness 
of arms and legs and some sensory changes. Patient B received surgery after 6 
years of disease duration because of an instable AAS of 13 mm in flexion without 
symptoms besides some stiffness of the neck. Both patients also received multiple 
other orthopaedic interventions related to RA. Patient A had one erosion and 
patient B had no erosions of the hands and feet at baseline. At 3 and 6 years, the 
Ratingen score for hands and feet was 8 and 12, respectively, for both patients 
which was lower than the median of the total group of patients with cervical spine 
damage at 9 years. At 9 years, patient A had a Ratingen score of 28 and patient B of 
42.  
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Comparison of the patients with or without cervical spine damage due to RA
Of the 134 patients with radiographs of the cervical spine at 9 years, 22 (16%) had 
cervical spine damage due to RA (erosions of C1, of C2, AAS, and/or AAI). Table 3 
shows the comparison of the patient characteristics, disease activity, functionality, 
number of previous DMARDs and number of erosions of the peripheral joints at 
baseline, 3, 6 and 9 years between patients with and without cervical spine damage 
at 9 years. The patient characteristics at baseline were comparable between the 
two groups. At 3 years, patients with cervical spine damage due to RA had a 
statistically significant higher disease activity than patients without cervical spine 
damage (4.46 (SD 1.37) vs 3.37 (SD 1.49), P=0.002). However, no differences in 
disease activity were observed at 6 and at 9 years (Table 3). Functionality was also 
similar between the two groups at all time points (Table 3). Patients with cervical 
spine damage at 9 years used a statistically significant higher median number of 
previous DMARDs at 3, 6 and 9 years (3 years: 2.5 [IQR 2.25] vs 2 [IQR 1], P = 
0.039; 6 years: 3 [IQR 1.25] vs 2 [IQR 2], P < 0.0001; 9 years: 4 [IQR 1] vs 3 [IQR 
3], P = 0.001). 
 Figure 1 shows the medians and ranges of erosions of hands and feet of the 
patients with and without cervical spine damage at 9 years at baseline, 3, 6 and 9 
Table 2: Prevalence of cervical spine damage due to RA at baseline, 3, 6, 9 and 12 years
Cervical spine  Baseline 3 years 6 years 9 years 12 years 
damage (n = 60) (n = 66) (n = 180) (n = 134) (n = 78)
Erosions of C1, 
number of  0 1 1 2 0*
patients 
Erosions of C2, 
percentage  4% 7.9% 10.1% 13.1% 20%
(number) (2/50) (5/63) (17/169) (17/130) (15/75)
AAS, percentage  0 4.8%  5.9% 7.3% 8.1%
(number)  (3/59) (10/170) (9/124) (6/68) 
AAI, number of 
patients# 0 0 1 1 1
*Erosions of C1 were not observed in the patients examined at 12 years. The patients with erosions of C1 
at 9 years were not included in this patient sample.
#AAI scored by the Clark method.
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Table 3: Patient characteristics, disease activity, functionality, number of previous DMARDs and 
number of erosions of the peripheral joints at baseline, 3, 6 and 9 years in patients with and without 
cervical spine damage at 9 years
 Patients with Patients without 
 cervical spine damage  cervical spine damage
 at 9 years at 9 years 
 (n = 22) (n = 112) P
Age, years (SD) 51.2 (12.6) 49.9 (13.1) 0.655
Female, number (%) 15 (68) 75 (67) 0.911
Rheumatoid factor 19 (86) 87 (78) 0.360
positive, number (%)
Baseline:    
    DAS28, mean (SD) 5.81 (1.14) 5.44 (1.39) 0.248
    HAQ, mean (SD) 0.74 (0.51) 0.62 (0.53) 0.388
 (n = 19) (n = 94)     
    Erosions of hands 3 (6.5) 1 (3) 
    and feet, median (IQR#) (n = 21) (n = 95) 0.130
3 years:   
    DAS28, mean (SD) 4.46 (1.37) 3.37 (1.49) 0.002
    HAQ, mean (SD) 0.59 (0.40) 0.51 (0.52) 0.531 
 (n = 19) (n = 91) 
    Number of previous 2.5 (2.25)     2 (1)**
    DMARDs, median (IQR) (n = 22) (n = 106) 0.039
    Erosions of hands 24 (27) 12 (17) 0.001
    and feet, median (IQR) (n = 21) (n = 96)
6 years:    
    DAS28, mean (SD) 3.99 (1.13) 3.59 (1.46) 0.222
    HAQ, mean (SD) 0.73 (0.55) 0.59 (0.58) 0.319
 (n = 20) (n = 95) 
    Number of previous 3 (1.25) 2 (2)** < 0.0001
    DMARDs, median (IQR) (n = 22) (n = 108)
    Erosions of hands 32 (35.5) 16 (18) < 0.0001
    and feet, median (IQR) (n = 20) (n = 91)
9 years:    
    DAS28, mean (SD) 3.51 (1.19) 3.69 (1.58) 0.617
    HAQ, mean (SD) 0.76 (0.58) 0.69 (0.63) 0.689
 (n = 19) (n = 101) 
    Number of previous 4 (1) 3 (3)†
    DMARDs, median (IQR) (n = 18)     (n = 109) 0.001
    Erosions of hands 37.5 (31.25) 19 (24.5) 
    and feet, median (IQR) (n = 18) (n = 89) < 0.0001
    
* no statistically significant difference. 
# interquartile range.
** one patient used adalimumab.
† 3 patients used adalimumab and 2 patients used infliximab.     
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years. Patients with cervical spine damage at 9 years had a statistically significant 
higher median number of erosions of the peripheral joints at 3, 6 and 9 years (3 
years: 24 [IQR 27[ vs 12 [IQR 17], P = 0.001; 6 years: 32 [IQR 35.5] vs 16 [IQR 18], 
P < 0.0001; 9 years: 37.5 [IQR 31.25] vs 19 [IQR 24.5], P < 0.0001). Figure 1 shows 
that all patients with cervical spine damage at 9 years had erosive disease of the 
peripheral joints at 3 years. On the other hand, if erosive disease of the hands and 
feet was absent at 3 years, cervical spine damage did not develop during the first 
9 years of follow-up. However, a wide range of erosive disease of the peripheral 
joints can be observed in both patients with and without cervical spine damage at 
9 years. 
P = 0.130       P = 0.001              P < 0.0001                       P < 0.0001
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Figure 1: Ratingen scores for erosions of hands and feet at baseline, 3, 6 and 9 years in patients with and 
without cervical spine damage at 9 years.
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Discussion
In this observational cohort of patients with early RA, cervical spine damage due 
to RA was observed in 16% of patients at 9 years. During the total of 12 years 
follow-up, AAS and erosions of C2 were most commonly observed. On the other 
hand, erosions of C1 and AAI were very rare with only a few patients affected. 
The frequency of erosions of C2 and AAS increased over the 12 years of follow-
up. Severe cervical spine damage was very rare: only 2 patients needed surgical 
intervention of the cervical spine. 
 Our results show that cervical spine damage due to RA is related to a higher 
disease activity at 3 years and a higher number of erosions in the peripheral joints 
at 3, 6 and 9 years. Besides, patients with cervical spine damage due to RA were 
treated with a higher number of DMARDs during the study period, which also 
indicates that these patients had a more active and severe disease. Our findings 
are in line with the results of previous studies, in which patients with a more 
aggressive erosive disease of the peripheral joints showed more damage of the 
cervical spine (14;17;18;31). Similar results have been found for other large joints, 
including the hips (31).   
 A wide range of prevalence from 17% up to 86% (5;6) of cervical spine damage 
due to RA was found in previous studies. The width of this range can be explained 
by a combination of factors such as the disease duration and disease severity of 
the RA population investigated, the type of cervical spine damage investigated, 
the assessments used to evaluate this damage, and the study design. The 
prevalence seems also to be dependent on the time period in which the study 
has been conducted. In historical studies from the 1960s till 1980s, cervical spine 
damage due to RA has been found in up to 86% of the patients studied (6;17;32). 
In studies after 1990, the prevalence is considerably lower with percentages up 
to about 45% (13;14;33-37). In our study, which was conducted in the period of 
1985 up to 2002, the prevalence of cervical spine changes was 16%. This marked 
decline in prevalence of cervical spine damage in the last decades observed in 
our and previous studies may be the result of more intensive treatment strategies 
with DMARDs in early RA (38-40), which was confirmed by the studies of Neva 
et al and Kauppi et al (13;21). The patients with early RA included in our study 
were treated with DMARDs according to the treatment guidelines for RA in The 
Netherlands during the study period. In the last decade, biological agents with 
several mechanisms of action, such as tumour necrosis factor-α-blocking agents 
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and B-cell depleting therapy, have become widely available. These biological 
agents have already proven to prevent or slow down radiologic progression of 
erosions of the peripheral joints (41-43). There is also evidence that infliximab 
can be used to suppress progression of cervical spine damage due to RA (44). To 
our knowledge, no extensive long-term prospective studies investigating cervical 
spine damage due to RA have yet been conducted in the biologic era. However, 
we assume that the prevalence will decrease in the following years when more 
intensive treatment strategies, including these biological agents, are used in an 
early stage of the disease. 
  Our study has some advantages in contrast to previous studies: a long-term 
prospective study with a follow-up time of at least 6 years with a maximum of 
12 years instead of previous cross-sectional or short-term prospective studies 
(5;13;14;15); radiographs at regular intervals of 3 years; detailed data about 
cervical spine damage due to RA scored by validated scoring methods; and data 
about disease activity, disability, and erosions of the hands and feet at the same 
moments as the radiographs of the cervical spine had been taken. However, 
this study has also limitations. First, there was unfortunately a high number 
of missing radiographs of the cervical spine. Although the study protocol 
prescribed to perform radiographs of the cervical spine at baseline and every 3 
years thereafter, the protocol was not accurately followed in practice. Besides, in 
the early years of the study, only the higher cervical levels were visualised and 
during follow-up the quality of radiographs was sometimes poor, resulting in a 
high number of missing scores. These missing radiographs and scores can lead to 
selection bias. One might be more inclined to perform radiographs of the cervical 
spine in those patients at risk for cervical spine damage, such as patients with an 
erosive disease of the peripheral joints. On the contrary, radiographs of those 
patients with active disease might be lost at the radiology department, because 
they are viewed more regularly than those without damage. We assume, however, 
that the missing radiographs and poor quality were randomly distributed. This 
assumption is supported by the fact that baseline characteristics of the 196 
patients in whom radiographs were present were similar compared with those of 
the 36 patients in whom radiographs were missing. Due to these missing data, we 
were not able to perform longitudinal analyses and measure change over time as 
we initially intended to do. Second, the scoring methods used in this study were 
validated using hard copies of conventional radiographs. From 2002, radiographs 
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were digitalized in our hospital. Since absolute and digital measurements are 
two separate entities because of difference in scale and methods we considered 
uniting both measurements not reliable. We chose therefore to restrict our 
analyses to the conventional radiographs obtained before 2002. Third, the intra- 
and interobserver reliability of scoring erosions of C2 was poor. This is probably 
the result of its low prevalence, although we corrected for this by adjusting the 
Cohen’s kappa for prevalence (30). Besides, erosions of C1 were absent in the set 
of radiographs selected for validation, as a result we were not able to calculate 
the intra- and interobserver reliability. Nevertheless, we decided to include these 
cervical spine changes in this study, because they are caused by inflammation of 
synovium due to RA. Finally, we did not record signs or symptoms suggestive 
for cervical spine damage due to RA in our patients. However, previous studies 
have shown that cervical spine damage is often asymptomatic and rarely causes 
neurological signs or symptoms (17;35;45;46).
 It is important to identify those patients at risk for complications due to cervical 
spine damage, especially prior to anaesthesia, in order to prevent severe disability 
and mortality (1;4). There are however no guidelines whether radiographs of the 
cervical spine should be performed on a regular base and previous studies have 
found contrasting results whether cervical spine radiographs are indicated prior 
to anesthesia (4;46-48). We observed that cervical spine damage, in particular 
SAS, could already be present in the early disease years. This was in contrast to 
the observations in a previous Dutch study in which cervical spine damage due 
to RA was rare in the first 5 years of disease (35). However, a previous study of 
Winfield et al. (45) also showed that over 80% of the patients developed the first 
evidence of subluxation within the first 2 years of disease onset. We also observed 
that patients without erosive damage at 3 years were unlikely to develop cervical 
spine damage within the first 9 years. Besides, severe cervical spine damage for 
which surgical intervention was needed was very rare. Our results showed a 
wide variance in presence of erosions of hands and feet in both patients with and 
without cervical spine damage at 9 years of follow-up. Notably, the two patients 
who needed surgical intervention of the cervical spine had a lower number of 
erosions in the hands and feet than the median of the total study population at 3 
and 6 years after disease onset. 
 From the results of this descriptive study, we can conclude that screening for 
cervical spine damage prior to anaesthesia or as part of routine follow-up is not 
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indicated in patients without erosive damage of the hands and feet at 3 years after 
disease onset except if signs or symptoms which might result from myelopathy 
are present. In patients with any degree of erosive disease of the hands and feet, 
rheumatologists should be aware of possible presence of cervical spine damage 
due RA early in the disease course. Radiographs of the cervical spine should be 
considered in these patients prior to anaesthesia. However, the need for routine 
screening for cervical spine damage and its clinical relevance is still not clear and 
should be further investigated. Furthermore, this study was conducted before 
biological agents became widely available. Future research is needed in order to 
investigate whether early and more intensive treatment might prevent cervical 
spine damage due to RA.  
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Abstract
Objective
To describe the frequency and effectiveness of dose increase of adalimumab, 
etanercept, and infliximab in the treatment of rheumatoid arthritis (RA) in daily 
clinical practice. 
Methods
All RA patients with a dose increase of tumor necrosis factor-α (TNF) blocking 
therapy between January 1997 and January 2008 were selected from a register 
including data from RA patients starting a first TNF blocking agent (the Dutch 
Rheumatoid Arthritis Monitoring register). The primary outcome was change 
in Disease Activity Score in 28 joints (DAS28) at 3 months after dose increase. 
Secondary outcomes were the change in DAS28 at 6 months after dose increase, 
the European League Against Rheumatism response rates, and the percentages 
of patients reaching a DAS28 of ≤ 3.2 at 3 and at 6 months after dose increase. 
Furthermore, the effectiveness of dose increase was assessed for the different 
reasons for dose increase: nonresponse, loss of response, and partial response. 
Results
During the study period, the dose was increased in 44 (12%) of the 368 
adalimumab patients, 32 (8%) of the 420 etanercept patients and 115 (36%) of 
the 323 infliximab patients. The change in DAS28 at 3 months and 6 months after 
dose increase was limited and only significant in etanercept patients at 3 months 
(-0.51; P = 0.035). Disease activity decreased significantly at 3 months from dose 
increase in the nonresponders and patients with loss of response (-0.66 and -0.99, 
respectively; both P = 0.001), but not in the partial responders.
Conclusion
Although dose increase was applied in all three TNF blocking agents in daily 
clinical practice, these results suggest that the effectiveness of dose increase is 
limited. 
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Introduction
Three tumor necrosis factor-a (TNF) blocking agents are currently available 
for the treatment of rheumatoid arthritis (RA) in daily clinical practice in the 
Netherlands: infliximab, adalimumab, and etanercept. Each of these agents has 
proven to be efficacious in the treatment of RA, with response rates up to 70% in 
the active treatment groups of randomized controlled trials (RCTs) (1-3). Despite 
these high response rates, the initial infliximab dose was increased in 31% of 
patients in daily clinical practice because of inadequate response to the initial 
dose during the first year of therapy, and in 7.1% and 4.8% of patients receiving 
adalimumab and etanercept, respectively (4). 
 Evidence about the effectiveness of dose increase of TNF blocking therapy is, 
however, doubtful and most studies have focused on infliximab. A dose increase 
of infliximab of 1.5 mg/kg was suggested to be effective in patients who had a lack 
of response or a flare to infliximab in a dose of 3 mg/kg (5). Another study showed 
that a dose increase with one vial of 100 mg might be effective in patients with 
a partial loss of response to the initial infliximab dosing scheme (6). However, 
other studies showed that the effect of a dose increase of infliximab was small 
(7;8) or not even better than continuing the initial dose after an incomplete 
response (9). In addition, increasing the dosage interval of adalimumab to 40 mg 
subcutaneously every week in patients with a lack of response to the initial dose 
did not add benefit and was not more effective than shortening the dosage interval 
in the placebo group (10). So far, no studies have been published investigating the 
effectiveness of a dose increase in patients receiving etanercept. Furthermore, an 
important consequence of dose increase is the higher cost of therapy. 
 The current study was therefore conducted to further investigate and describe 
the frequencies and effectiveness of dose increase in three TNF blocking agents, 
adalimumab, etanercept, and infliximab, in the treatment of patients with RA in 
daily clinical practice. 
Methods
Patients
For this descriptive study, data were used from the Dutch Rheumatoid Arthritis 
Monitoring (DREAM) register. This register includes patients with RA who 
started treatment with a TNF blocking agent for the first time in daily clinical 
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practice, and it was initially started in January 1997 in one hospital (the Radboud 
University Nijmegen Medical Centre). Since February 2003, the register contains 
data from eleven hospitals. At inclusion, patients were at least 18 years of age 
and fulfilled the 1987 American College of Rheumatology (ACR; formerly the 
American Rheumatism Association) criteria for RA (11). In addition, patients 
had to satisfy the Dutch criteria for reimbursement of TNF blocking therapy: 
at least moderate to high disease activity (Disease Activity Score in 28 joints 
[DAS28] ≥ 3.2) and failure of at least two disease-modifying antirheumatic drugs 
(DMARDs), including optimal doses of methotrexate (MTX, 25 mg per week 
with folic acid supplement). For this study, the ethics committee decided that no 
ethical approval was required. 
Therapy
During the study period, the TNF blocking agents available were adalimumab, 
etanercept, and infliximab. The choice of the TNF blocking agent and the dosing 
scheme were at the discretion of the attending rheumatologist. In general, patients 
started with TNF blocking agents following Dutch standard dosages: etanercept 
25 mg given subcutaneously twice weekly (later changed to 50 mg subcutaneously 
weekly), adalimumab 40 mg given subcutaneously every two weeks, or infliximab 
3 mg/kg given intravenously every eight weeks after loading doses at weeks 0, 2, 
and 6. According to the Dutch product information, the infliximab dose can be 
increased if it is not effective from 12 weeks with steps of 1.5 mg/kg to a maximum 
dosage of 7.5 mg/kg every 8 weeks, or with a shortening of the dosage interval to a 
maximum of 3 mg/kg every 4 weeks. For adalimumab, the dosage interval may be 
shortened to 40 mg weekly if it is not effective. No recommendations have been 
formulated for the dose increase of etanercept. There was no fixed protocol for 
dose increase during the study period. Therefore, the decision to increase the dose 
of TNF blocking therapy was at the discretion of the attending rheumatologist. 
Dose increase was possible without approval of the insurance companies. 
Treatment with a TNF blocking agent could be combined with DMARDs and/or 
corticosteroids. Start and stop dates, doses, changes in doses, and the reasons for 
change were registered. 
Outcomes and statistical analyses
All patients who started a first TNF blocking agent prior to January 2008 were 
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included in this analysis. Because we were interested in the effectiveness of dose 
increase in only those patients who continued the same TNF blocking therapy, 
analyses were performed according to a per-protocol principle. 
 For the analyses, the total dosages of TNF blocking therapy were calculated 
and expressed in milligrams (mg) per two weeks for adalimumab, in mg twice 
weekly for etanercept, and in mg/kg per 8 weeks for infliximab. In this calculation 
changes in dosage interval were included.
 At the start of the TNF blocking therapy, patient characteristics were registered, 
including age, sex, disease duration, rheumatoid factor (RF) status, previous 
DMARDs used, and the presence of one or more erosions in the hands or feet. 
These characteristics were expressed as mean ± SD or as median (interquartile 
range [IQR]) as appropriate. The three agents were compared using the Pearson’s 
Chi-square test for categorical data and using one-way analysis of variance or the 
Kruskal-Wallis nonparametric test for continuous data. 
 Disease activity was determined using the DAS28 (12), which was assessed by 
a trained study nurse at baseline, every three months for the first two years, and 
every six months thereafter. When the DAS28 was missing due to a missing value 
for the erythrocyte sedimentation rate (ESR), the ESR was imputed by means of 
single imputation by linear multivariate regression analysis using the values of the 
tender joint count, swollen joint count, and visual analogue scale score for general 
health of the patient. 
 We expected that increasing the dose of TNF blocking therapy would be effective 
shortly after dose increase. Therefore, the primary outcome was the change in 
DAS28 at 3 months compared with the DAS28 before the dose increase using the 
paired Student’s t test. The secondary outcomes were the change in DAS28 at 6 
months after dose increase compared with the DAS28 before the dose increase, 
the response rates defined by the European League Against Rheumatology 
(EULAR) response criteria (13) at 3 and at 6 months after dose increase, and the 
percentages of patients who reached a DAS28 of ≤ 3.2 at 3 and at 6 months after 
dose increase. 
 In order to identify a subgroup of patients in whom a dose increase might be 
more beneficial, the effectiveness of the dose increase was determined by the 
reason for dose increase. Three reasons for dose increase were retrospectively 
defined: nonresponse, loss of response, and partial response. Nonresponse was 
defined as nonresponse according to the EULAR response criteria, loss of response 
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was defined as an increase of ≥ 0.6 in the DAS28 at dose increase compared with 
the lowest DAS28 before dose increase after an initial good or moderate EULAR 
response, and partial response was defined as an initial EULAR response without 
an increase of disease activity. Primary and secondary analyses were repeated in 
the three subgroups.
 All analyses were performed using the SPSS statistical package, version 16.0 
(SPSS). P values less than 0.05 were considered significant.
Results
Baseline characteristics
Between January 1997 and January 2008, a total of 1,111 patients started a 
TNF blocking agent: 368 patients received adalimumab, 420 patients received 
etanercept, and 323 patients received infliximab as the initial agent. The maximum 
follow-up time was 55 months in the adalimumab patients, 96 months in the 
etanercept patients, and 94 months in the infliximab patients. 
 During this study period, the dose, interval, or both were increased in 44 
(12.0%) of the 368 patients receiving adalimumab, in 32 (7.6%) of the 420 patients 
receiving etanercept, and in 115 (35.6%) of the 323 patients receiving infliximab. 
Dose increase was achieved for all patients receiving adalimumab by shortening 
the dosage interval; for the 32 etanercept patients, it was achieved by shortening 
the dosage interval in 20 (62.5%), by increasing the dose in 8 (25%), and by 
doing both in 4 (12.5%); and for the 115 infliximab patients, it was achieved by 
shortening the dosage interval in 49 (42.6%), by increasing the dose in 61 (53.0%), 
and by doing both in 5 (4.3%).
 The median time to dose increase in this study was 10.5 months (IQR 14.3 
months) in patients receiving adalimumab, 9.0 months (IQR 11.3 months) 
in patients receiving etanercept, and 6.0 months (IQR 3.0 months) in patients 
receiving infliximab. The dosage was increased from a mean of 40 mg every other 
week to a mean ± SD of 73.9 ± 18.5 mg every other week in the adalimumab 
patients, from a mean ± SD of 23.3 ± 4.7 mg to 36.5 ± 5.4 mg twice weekly in the 
etanercept patients, and from a mean ± SD of 3.3 ± 0.6 mg/kg to 5.2 ± 1.3 mg/kg 
every 8 weeks in the infliximab patients. 
 At 3 months, 6 (13.6%) of the 44 adalimumab patients, 4 (12.5%) of the 32 
etanercept patients, and 8 (7.0%) of the 115 infliximab patients had discontinued 
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therapy within 3 months after dose increase, and at 6 months, 11 (25%) of the 
adalimumab patients, 5 (15.6%) of the etanercept patients, and 20 (17.4%) of the 
infliximab patients had discontinued therapy within 6 months after dose increase. 
According to the per-protocol analyses, the results of these data were not included 
Table 1: Characteristics for each of the TNF blocking agents at dose increase*
 Adalimumab Etanercept Infliximab 
 (n=44) (n=32) (n=115) P
Women	 30	(68.2)	 22	(68.8)	 84	(73.0)	 ns
Age,	mean	±	SD	years	 52.3	±	14.0	 56.2	(12.6)	 57.5	(12.3)	 ns
Disease	duration,	median	
(25th,	75th	percentile)	years	
7.1	(2.7-11.7)	 4.0	(1.7-9.6)	 9.6	(3.9-16.3)	 0.002
Rheumatoid	factor	 27	(64.3)†	 25	(78.1)	 95	(82.6)	 0.050
Erosions‡	 27	(61.4)	 14	(45.2)§	 40	(72.7)¶	 0.040
DAS28	at	increase,	mean	±	SD#	 4.1	±	1.2	 4.3	±	1.1	 4.3	±	1.4	 ns
HAQ	at	increase,	mean	±	SD**	 1.0	±	0.6	 1.4	±	0.7	 1.2	±	0.7	 ns
Prior	DMARDs,	median	
(25th,	75th	percentile)	
3	(2-4)	 3	(2-3)	 3	(2-5)	 0.017
Concomitant	MTX	 29	(65.9)	 18	(56.3)	 87	(75.7)	 ns
Concomitant	other	DMARD	 18	(40.9)	 18	(56.3)	 62	(53.9)	 ns
Corticosteroids	 13	(29.5)	 11	(34.4)	 32	(27.8)	 ns
*Values are the number (percentage) unless otherwise indicated. TNF = tumor necrosis factor; ns = 
not significant; DAS28 = Disease Activity Score in 28 joints; HAQ = Health Assessment Questionnaire; 
DMARDs = disease-modifying antirheumatic drugs; MTX = methotrexate.
† Percentage taken from 42 patients.
‡ At least 1 erosion in hands and feet.
§ Percentage taken from 31 patients.
¶ Percentage taken from 55 patients.
# Data was missing in 4 (9.1%) of 44 patients receiving adalimumab, in 2 (6.3%) of 32 patients receiving 
etanercept, and in 10 (8.7%) of 115 patients receiving infliximab.
** Data was missing in 5 (11.4%) of 44 patients receiving adalimumab, in 3 (9.4%) of 32 patients 
receiving etanercept, and in 41 (35.7%) of 115 patients receiving infliximab. 
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in the analyses. A small number of patients did not reach 3 or 6 months of follow-
up and were therefore censored: 5 (11,4%) of the adalimumab patients, 2 (6.3%) 
of the etanercept patients, and 1 (0.9%) of the infliximab patients at 3 months and 
9 (20.5%) of the adalimumab patients, 4 (12.5%) of the etanercept patients, and 
2 (1.7%) of the infliximab patients at 6 months. The DAS28 at dose increase or 3 
months thereafter was missing in 12 (36.4%) of the 33 patients remaining in the 
adalimumab group, 8 (30.8%) of the 26 patients in the etanercept group, and 32 
(30.2%) of the 106 patients in the infliximab group. The DAS28 at dose increase 
or 6 months thereafter was missing in 9 (37.5%) of the 24 remaining in the 
adalimumab group, 9 (39.1%) of the 23 remaining in the etanercept group, and 
27 (29.0%) of the 93 remaining in the infliximab group. The missing scores were 
random because assessment visits had not taken place within the time window of 
the follow-up moments chosen for these analyses. In total, data from 21 (63.6%) 
of the 33 adalimumab patients, 18 (69.2%) of the 26 etanercept patients, and 74 
(69.8%) of the 106 infliximab patients were available for the primary outcome at 
3 months and data from 15 (62.5%) of the 24 adalimumab patients, 14 (60.9%) 
Primary outcome
Change DAS28 
at 3 months, mean ± SD
Secondary outcomes
Response at 3 months‡
DAS28 at 3 months ≤ 3.2 
Change in DAS28 
at 6 months, mean ± SD
Response at 6 months‡
DAS28 at 6 months ≤ 3.2
Adalimumab
(n=44)
-0.25 ± 1.04
9/21 (42.9)
8/21 (38.1)
-0.27 ± 0.74
3/15 (20)
7/17 (41.2)
Etanercept
(n=32)
-0.51 ± 0.94†
9/18 (50)
6/19 (31.6)
0.15 ± 1.34
2/14 (14.3)
4/14 (28.6)
Infliximab
(n=115)
-0.22 ±1.30
26/74 (35.1)
8/77 (23.4)
-0.26 ± 1.31
22/66 (33.3)
19/70 (27.1)
Table 2: The effectiveness of dose increase at 3 and at 6 months after dose increase for each of the 
TNF blocking agents*
* Values are the number/total (percentage) unless otherwise indicated. All analyses were performed per 
protocol. See Table 1 for definitions. 
†Significant within patient.
‡ Defined as a good or moderate European League Against Rheumatism response.
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of the 23 etanercept patients, and 66 (71%) of the 93 infliximab patients were 
available for analyses of the secondary outcomes at 6 months.
 For each agent, the characteristics at dose increase are shown in Table 1. 
Infliximab patients had a significantly longer disease duration (P = 0.002), were 
Table 3: Baseline characteristics by reason for dose increase*
  Loss Partial
 Nonresponse of response response
 (n=36)†  (n=38)† (n=76)† P
Women	 25	(69.4)	 26	(68.4)	 53	(69.7)	 ns
Age,	mean	±	SD	years	 59.1	±	13.9	 53.6	±	12.1	 55.8	±	12.0	 ns
Disease	duration,	median	
(25th,	75th	percentile)	years	
11.0	(4.3-16.4)	 6.8	(3.7-11.9)	 7.0	(3.1-13.9)	 ns
Rheumatoid	factor	 27	(77.1)‡	 28	(73.7)	 61	(80.3)	 ns
Erosions§	 20	(64.5)	 22	(73.3)	 32	(60.4)	 ns
DAS28	at	increase,		
mean	±	SD	
5.5	±	1.1	 4.5	±	1.0	 3.7	±	1.1	 <0.0001
HAQ	at	increase,	
mean	±	SD¶	
1.6	±	0.7	 1.1	±	0.7	 1.1	±	0.7	 0.004
Prior	DMARDs,	
median	(25th,	75th	percentile)	
3	(3-4)	 3	(2-4)	 3	(2-4)	 ns
Concomitant	MTX	 27	(75.0)	 31	(81.6)	 46	(60.5)	 ns
Concomitant	other	DMARD	 15	(41.7)	 17	(44.7)	 41	(53.9)	 ns
Concomitant	oral	corticosteroids	 15	(41.7)	 12	(31.6)	 16	(21.1)	 	 ns
* Values are the number (percentage) unless otherwise indicated. See Table 1 for definitions.
† Reason for discontinuation could not be determined due to missing values of the DAS28 at baseline, 
at dose increase, or the lowest DAS28 before dose increase in 10 (22.7%) of 44 in the adalimumab group, 
3 (9.4%) of 32 in the etanercept group, and 28 (24.3%) of 115 in the infliximab group. 
‡ N=35 patients.
§ At least 1 erosion in the hands or feet. For nonresponse n=31 patients, for loss of response n=30 
patients, and for partial response n=53 patients.
¶ Data were missing in 6 (16.7%) of 36 in the nonresponse group, in 2 (5.3%) of 38 in the loss of response 
group, and in 15 (19.7%) of 76 in the partial response group.
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more often RF positive (P = 0.050), more often had an erosive disease (P = 0.040), 
and had failed more prior DMARDs (P = 0.017) than adalimumab patients and 
etanercept patients. 
The effectiveness of dose increase of adalimumab, etanercept, and infliximab
The improvement in disease activity at 3 months after dose increase was small in 
all three TNF blocking agents and was only significant in the patients receiving 
etanercept (P = 0.035) (Table 2). At 6 months after dose increase, no significant 
changes in disease activity were observed. Response rates at 3 and at 6 months 
were also limited, as were the percentages of patients reaching low disease activity 
(Table 2). The mean ± SD DAS28 reached at 3 and at 6 months after dose increase 
were 4.0 ± 1.3 and 3.7 ± 1.3 in the adalimumab patients, 4.0 ± 1.6 and 4.5 ± 1.3 
in the etanercept patients, and 4.2 ± 1.0 and 3.8 ± 1.3 in the infliximab patients, 
respectively, which still reflected moderate disease activity. 
Figure 1: mean DAS28 (95%CI) at baseline, lowest DAS28, DAS28 at dose increase and at 3 months and 
at 6 months thereafter by reason for dose increase.
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The effectiveness of dose increase by reason for dose increase
The reason for dose increase could be defined in 150 (78.5%) of the 191 patients 
with a dose increase. In the other 41 patients (21.5%), data about the DAS28 at 
baseline, the lowest DAS28 before dose increase, and/or the DAS28 at the time of 
Table 4: The effectiveness of dose increase at 3 and 6 months after dose increase by reason for 
dose increase*
 Nonresponse   Loss of response   Partial response
 (n=36)  (n=38)  (n=76)
Primary outcome   
Change  in DAS28 at 
3 months, mean ± SD† 
-0.66 ± 0.92‡ -0.99 ± 1.15† 0.05 ± 1.04
Secondary outcomes   
Response at 3 months§ 11/25 (44.0) 13/22 (59.1) 16/52 (30.8)
DAS28 at 3 months ≤ 3.2 3/25 (12.0) 10/22 (45.5) 16/52 (30.8)
Change in DAS28 at 
6 months, mean ± SD¶ 
-0.86 ± 1.30‡ -0.33 ± 1.15 -0.12 ± 1.14
Response at 6 months§ 9/17 (52.9) 5/19 (26.3) 11/46 (23.9)
DAS28 at 6 months ≤ 3.2 2/17 (11.8) 4/19 (21.1) 18/46 (39.1)
* Values are the number/total (percentage) unless otherwise indicated. All analyses were performed per 
protocol. See Table 1 for definitions.
† At 3 months, 6 (16.7%) of the 36 nonresponders, 2 (5.3%) of the 38 patients with loss of response, and 
7 (9.2%) of the 76 partial responders to the initial dose discontinued therapy within 3 months after dose 
increase, and none, 2 (5.3%), and 3 (3.9%) were censored, respectively, because they did not reach 3 
months of followup at the end of the study period. The DAS28 at dose increase or 3 months thereafter 
was missing in 5 (16.7%) of the 30 nonresponders, in 12 (35.3%) of the 34 patients with loss of response, 
and in 14 (21.2%) of the partial responders to the initial dose.
‡ Significant within patient. 
§ Response is defined as good or moderate European League Against Rheumatism response.
¶ At 6 months, 11 (30.6%) of the 36 nonresponders, 6 (16.7%) of the 38 patients with loss of response, 
and 11 (14.5%) of the 76 partial responders to the initial dose discontinued therapy within 6 months 
after dose increase, and 1 (2.8%), 5 (13.2%), and 6 (7.9%) were censored, respectively, because they did 
not reach 6 months of followup at the end of the study period. The DAS28 at dose increase or 6 months 
thereafter was missing in 7 (29.2%) of the 24 nonresponders, in 8 (29.6%) of the 27 patients with loss of 
response, and 13 (22.0%) of the 59 partial responders to the initial dose. 
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dose increase were missing. 
 Nonresponse was the reason for dose increase in 36 (24%) of the 150 patients, 
loss of response in 38 (25.3%) of the patients, and partial response in 76 (50.7%) of 
the patients. In the adalimumab group, most patients had a dose increase because 
of loss of response (41.2%). However, partial response was the most frequent 
reason for dose increase in the patients receiving etanercept (51.7%) and in those 
receiving infliximab (56.3%).
 The characteristics of the patients by reason for dose increase at dose increase 
are shown in Table 3. As expected, the mean DAS28 at the time of dose increase 
was significantly higher in the nonresponders compared with the other two 
groups (P <0.0001). 
 The mean DAS28 at the start of TNF blocking therapy, the lowest DAS28 
prior to dose increase, the DAS28 at dose increase, and the DAS28 at 3 and at 6 
months thereafter for each reason for dose increase are shown in Figure 1. In the 
nonresponders, disease activity improved significantly at 3 and at 6 months (P = 
0.001 and P = 0.014) (Table 4). However, only 12% of the nonresponders reached 
low disease activity. In the patients with a dose increase due to loss of response, 
disease activity improved significantly only at 3 months, but not at 6 months (P 
= 0.001 and P = 0.221) (Table 4). Disease activity did not change in the partial 
responders at either 3 or at 6 months after dose increase (Table 4). 
Discussion
This study was conducted to describe the frequency and effectiveness of dose 
increase in three TNF blocking agents, adalimumab, etanercept, and infliximab, in 
the treatment of patients with RA in daily clinical practice. This study showed that 
in one-third of the patients receiving infliximab, the initial dose was increased. In 
patients receiving adalimumab or etanercept, these proportions were considerably 
lower. If the dose was increased, the effectiveness was very small or lacking for all 
three TNF blocking agents. 
 In the subgroups by reason for dose increase, the effectiveness of dose increase 
was determined in order to identify a group of patients in whom dose increase 
might be beneficial. Our results suggest that dose increase might be effective in 
primary nonresponders, although the disease activity remained moderate at 3 
and 6 months after dose increase. The effect of dose increase was small in patients 
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with loss of response and in partial responders to the initial dose. 
 The effectiveness of the dose increase found in our study in the patients receiving 
infliximab is comparable with the effectiveness found in previous studies by Van 
Vollenhoven et al, Van Vollenhoven and Klareskog, and Pavelka et al,(7-9) which 
concluded that the gain of dose increase of infliximab was small, or not even 
better than that in the control group in which the dose was not increased. In 
contrast, another study in which the effect of dose increase after nonresponse or 
loss of response to infliximab was investigated showed an ACR 20% improvement 
criteria response rate in up to 80% of the subjects (5). In a study by Bartelds 
et al, dose increase led to a mean ± SD decrease in DAS28 of 1.7 ± 1.2 in 7 
nonresponders to adalimumab (14). So far, no studies to our knowledge have 
been published investigating the effect of a dose increase in patients receiving 
etanercept in daily clinical practice. It should be noted that all abovementioned 
studies were observational studies except the one by Pavelka et al (9). As reported 
by Van Vollenhoven, those improvements shown in observational studies 
might represent regression to the mean (15). This could very well explain the 
contradictory results mentioned above.
 There are a few possible explanations for why a dose increase was more frequently 
observed in patients receiving infliximab than in those receiving adalimumab or 
etanercept in our study. First, recommendations for dose increase or shortening 
of the dosage interval are described in the product information of infliximab and 
adalimumab, but not in that of etanercept. Therefore, it was surprising that the 
dose of etanercept was increased in 8% of the patients of our study population, 
which was possible because dose increase was independent of approval of the 
insurance companies in The Netherlands. Second, because infliximab was the first 
TNF blocking agent available, rheumatologists might have been inclined to try a 
dose increase in case of lack of effect because other options were not available yet. 
However, this did not affect the effectiveness of the dose increase in infliximab, 
which was comparable when only analysing those patients who started infliximab 
after the availability of adalimumab and etanercept (data not shown). Third, the 
possibilities for the dose increase of infliximab may be more subtle. A fourth 
possible explanation may be the difference in immunogenicity between the three 
TNF blocking agents, because previous studies have shown that patients receiving 
infliximab have more antibody formation than patients receiving adalimumab 
(14;16-18). Antibody formation may be associated with lower or undetectable 
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serum levels of the agent and may lead to adverse events and loss of effect (14;16-
19). Dose increase can be the solution to induce higher serum levels of the agent 
and to maintain low disease activity (5;14;16). Unfortunately, antibody formation 
and serum levels of the agents were not assessed in our study.  
 The observational design of this study had advantages and disadvantages. 
The results of this study reflect the effect of TNF blocking agents in daily 
clinical practice closely. On the other hand, the percentage of missing data 
is considerable. Missing data could have resulted in an overestimation of the 
effect if nonresponders especially had missing data. However, data were mostly 
missing at random, and patients were assessed even when they stopped receiving 
TNF blocking agents. Furthermore, because the results of this study are already 
negative, we do not think that complete data could have changed our conclusions. 
Another limitation inherent to observational design is the lack of a control group. 
It would have been interesting to compare the effectiveness of dose increase of 
TNF blocking therapy with the effectiveness of therapy on stable dose. However, 
the observational design of this study was not appropriate for this kind of analysis. 
The most important reason for this is that the results might be confounded by 
indication because patients who need a dose increase will have a more active and 
therapy-resistant disease than those who do not need a dose increase. However, 
the fact that we showed no additional effect of dose increase (i.e., a negative result) 
makes the chance for a false-positive result zero. Therefore, there is no need for a 
control group seen from a methodologic point of view, and we only analysed the 
effectiveness of dose increase within the patients who needed a dose increase. On 
the other hand, we observed that a dose increase might be beneficial in primary 
nonresponders. In order to investigate whether this is a real effect or regression to 
the mean, further research with a control group is needed. 
 An important consequence of dose increase is the higher cost of therapy. A dose 
increase in 8%-36% of patients will result in an increase of 40%-80% of the total 
costs of TNF blocking agents (data not shown). Furthermore, Van Vollenhoven 
estimated that worldwide, approximately €1 billion has been spent unnecessarily 
on infliximab (15). Additionally, Pavelka et al showed that the number of serious 
adverse events was higher in higher dose groups (9). The increase in costs and 
adverse events related to dose increase stress the urgency of raising awareness 
among rheumatologists that antirheumatic drugs should be used optimally. 
Furthermore, the fact that the effectiveness of dose increase of TNF blocking 
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therapy was very limited in our study raises the question of whether other 
therapeutic options might be more (cost-) effective in patients with inadequate 
response to TNF blocking therapy. 
 In conclusion, the results of this descriptive study suggest that although 
dose increase is frequently applied in adalimumab, infliximab, and etanercept 
in daily clinical practice, the effectiveness of dose increase is limited. Only in 
nonresponders to the initial dose, dose increase might be beneficial, although 
disease activity was still moderate after dose increase. Therefore, the effectiveness 
of other therapeutic strategies, such as switching to a second TNF blocking 
agent or a biological agent with another mechanism of action, should be further 
investigated in patients with inadequate response to the first TNF blocking agent.
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The reason for discontinuation of the first tumor 
necrosis factor-α (TNF) blocking agent does not influence 
the effect of a second TNF blocking agent in patients 
with rheumatoid arthritis 
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Objective 
To investigate whether the reason for discontinuation of the first tumor necrosis 
factor-α (TNF) blocking agent influences the effect of a second TNF blocking 
agent. 
Methods 
Data were used from two Dutch registers including patients with rheumatoid 
arthritis (RA) treated with TNF blocking agents. Patients were divided in three 
groups based on the reason for discontinuation of the first: nonresponse, loss 
of response, or adverse events. The primary outcome was the change from 
baseline of the disease activity (by DAS28) at 6 months, corrected for the baseline 
DAS28. Secondary outcomes were the change from baseline at 3 months, EULAR 
response rates and the percentages of patients who reached a DAS28 ≤ 3.2 at 3 
and at 6 months. 
Results 
In total, 49 patients who failed due to nonresponse, 75 who failed due to loss of 
response, and 73 who failed due to adverse events were included. At 6 months, 
the change of DAS28 from baseline did not differ significantly between the groups 
(-0.6 to -1.3, P ≥ 0.173) and similar good and moderate response rates were found 
(12 to 18%, P ≥ 0.523 and 34 to 55%, P ≥ 0.078, respectively). The secondary 
outcomes were also comparable between the three groups.  
Conclusion 
The results of our observational study suggest that a second TNF blocking agent 
may be effective after failure of the first, regardless of the reason for discontinuation 
of the first TNF blocking agent.
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Introduction
Tumour necrosis factor-a (TNF) blocking agents have been shown to be efficacious 
in the treatment of rheumatoid arthritis (RA) with response rates up to 70% (1-3). 
However, 21-35% of the patients who started treatment with a TNF blocking agent 
discontinued these agents within the first year due to either lack of effect or adverse 
events (4-6). Studies have shown that a switch to a second TNF blocking agent may 
be beneficial in patients who failed the first (7-15). 
 Although it seems against expectations that a patient who failed a TNF blocking 
agent may benefit from switching to another TNF blocking agent, there are some 
biochemical explanations. All three TNF blocking agents currently available, 
infliximab, adalimumab and etanercept, target TNFα; however, biochemical 
structures and properties differ. Although formation of human anti-chimeric 
antibodies (HACAs) or human anti-human antibodies (HAHAs) (16-18) can lead 
to either secondary loss of response or adverse events, there is no indication that 
antibodies against one TNF blocking agent influence the effect of a second TNF 
blocking agent (19). 
 On the other hand, lack of response to a TNF blocking agent may be caused 
by genetic variation within the TNFA gene or other candidate genes within the 
TNF-α pathway (20;21). Taking this underlying mechanism into account, it is 
conceivable that a patient who showed no response to the first TNF blocking agent 
will also fail to respond to a second TNF blocking agent. Therefore, the reason for 
discontinuation of the first TNF blocking agent, in this case nonresponse, may be 
a reason not to switch to a second TNF blocking agent. 
 The aim of this study was therefore to investigate whether the reason for 
discontinuation of the first TNF blocking agent influences the effect of treatment 
with a second TNF blocking agent. 
Methods
Patients
Data from two register were used: the local register of the Radboud University 
Nijmegen Medical Centre, which was started in 1997, including patients with RA 
who started treatment with a TNF blocking agent in daily clinical practice at the 
university hospital; and the Dutch RhEumatoid Arthritis Monitoring (DREAM) 
register, which was started in February 2003. In the latter, data were collected 
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from RA patients treated with TNF blocking agents at eleven hospitals (22). 
At the time of the analysis, the local register contained complete data until July 
2006 and the DREAM register until December 2007. Both registers had similar 
inclusion criteria and data collection. Therefore, data could be combined for the 
analyses. All patients fulfilled the 1987 American College of Rheumatology (ACR) 
criteria for RA (23). Patients of both cohorts also satisfied the Dutch criteria for 
reimbursement for treatment with a TNF blocking agent: moderate to high disease 
activity (Disease Activity Score in 28 joints (DAS28) ≥ 3.2); and failure of at least 
two disease-modifying antirheumatic drugs (DMARDs) including optimal doses 
of methotrexate (MTX, 25 mg per week). The study protocol was submitted to the 
ethics committee. Since both registers contain data from daily clinical practice, the 
ethics committee determined that no ethical approval was required. 
 For the analysis, patients were retrospectively divided into three groups by 
reason for discontinuation of the first TNF blocking agent. The first group, the 
nonresponders, consisted of patients who failed due to lack of effect according to 
their attending rheumatologist and who showed no good or moderate response 
using the European League Against Rheumatology (EULAR) response criteria 
(24) based on the best DAS28 during the total time of use of the first TNF blocking 
agent. The second group included patients who failed the first TNF blocking agent 
due to secondary loss of response after initial good or moderate EULAR response, 
based on the best DAS28 during the total time of use of the first TNF blocking 
agent. The third group consisted of patients who failed the first TNF blocking agent 
due to adverse events. If both lack of effect and adverse events were reported as the 
reason for discontinuation of the first TNF blocking agent by the rheumatologist, 
we considered lack of effect as the main reason for discontinuation. 
Treatment
The choice of the TNF blocking agent and the dosing scheme were at the discretion 
of the attending rheumatologist. In general, patients started with TNF blocking 
agents following Dutch labeled doses: infliximab 3 mg/kg given intravenously 
every eight weeks after a loading dose at week 0, 2 and 6; etanercept 25 mg 
subcutaneously twice weekly; or adalimumab 40 mg subcutaneously every two 
weeks. Treatment with a TNF blocking agent could be combined with DMARDs 
and/or corticosteroids. Start and stop dates, doses and reasons for changes were 
recorded.
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Outcomes
Baseline characteristics were registered at the start of the second TNF blocking 
agent, including age, sex, disease duration, number of previous DMARDs, and 
rheumatoid factor status. A trained study nurse (both registers) or the attending 
rheumatologist (hospital register) assessed patients at the start of the first TNF 
blocking agent and every three months thereafter. A switch to the next TNF 
blocking agent could be made at any time, that is, irrespective of the timing of the 
clinical assessments. The assessments included tender and swollen joint counts 
(TJC and SJC), erythrocyte sedimentation rates (ESR), and the visual analogue 
scale for general health (VASGH). The DAS28 was calculated to evaluate disease 
activity (25). For the analyses, assessments were used from baseline (> -3 and ≤ 0 
months), 3 (> 1.5 and ≤ 4.5 months), and 6 months (> 4.5 and ≤ 7.5 months). In 
case of missing DAS28 scores caused by a missing value for the ESR, the ESR was 
imputed by means of linear multivariate regression using the patient’s values for 
TJC, SJC, and VASGH.
 The primary outcome was the change from baseline in DAS28 after 6 months 
of the second TNF blocking agent. Secondary outcomes were the change from 
baseline in DAS28 at 3 months; the EULAR response rates (good and moderate) 
at 3 and 6 months; the percentages of patients who reached a DAS28 of ≤ 3.2 at 3 
and 6 months; and the drug survival of the second TNF blocking agent. 
Analyses
Data for all patients who started a second TNF blocking agent prior to January 
2006 (hospital register) or June 2007 (DREAM register) were selected for analyses. 
January 2006 and June 2007 were chosen so that all patients had at least 6 months 
of follow-up at the time of the analyses. Analyses were performed per protocol so 
that the results represent daily clinical practice. 
 Baseline characteristics were expressed as mean (SD) or as median (range) as 
appropriate and compared between the three groups using the Pearson’s Chi-
squared test for categorical data and one-way ANOVA or the non-parametric 
Kruskal-Wallis test for continuous data. The primary outcome, the change 
from baseline in DAS28 at 6 months, was compared between the groups using 
multiple linear regression analysis with correction for disease activity and use 
of corticosteroids at baseline. This method was also used to compare the change 
from baseline at 3 months between the groups. The change from baseline at 3 and 
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6 months within the three groups was analyzed using the paired Student’s t test. 
The response rates and percentages of patients who reached a DAS28 ≤ 3.2 were 
compared between the groups by the Pearson Chi-squared test. Kaplan-Meier 
survival analysis was used to assess drug survival and the Log-rank test was used 
to compare the survival curves. To correct for multiple comparisons, a Bonferroni 
correction was performed and an adjusted α of 0.017 (0.05/3) was considered 
significant. 
 Analyses were performed using SPSS version 14.0 (SPSS Inc., Chicago, Illinois, 
USA).
Results
Baseline characteristics
A total of 245 patients with RA were identified who failed a first TNF blocking 
agent and switched to a second prior to January 2006 (hospital register) or 
June 2007 (DREAM register). Of these patients, 20 (8%) were excluded since 
they discontinued the first TNF blocking agent due to reasons other than lack 
of effect or adverse events, such as wish to go into pregnancy, need for surgery, 
or discontinuation by patient’s own initiative. Of the remaining 225 patients, 
197 (88%) had complete data, with a baseline DAS28 and a best DAS28 during 
treatment with the first TNF blocking agent. These patients were classified into 
three groups: 49 nonresponders, 75 who failed due to loss of response, and 73 who 
failed due to adverse events. The median time intervals to achieve the best DAS28 
during use of the first TNF blocking agent in nonresponders, in patients who 
failed due to loss of response and in those who failed due to adverse events was 
2.2 months (0-11.5), 5.5 months (0.8-34.1) and 2.8 months (0-15.2), respectively 
(P < 0.0001). 
 Table 1 shows the baseline characteristics. No differences were observed 
between the groups regarding sex, age, disease duration, rheumatoid factor status, 
and number of previous DMARDs. Infliximab was used more frequently (P = 
0.010) as the first TNF blocking agent in patients who failed due to adverse events 
compared to the other two groups. All patients had active disease at the start 
of the second TNF blocking agent. However, disease activity was significantly 
higher in the nonresponders compared to the patients who failed due to loss of 
response and those who failed due to adverse events (P < 0.0001). In addition, 
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* Missing data in 2% (1/49) in A. **Missing data in A, B and C, 14% (7/49), 9% (7/75) and 16% (12/73), 
respectively. RF: rheumatoid factor; DMARD: disease-modifying antirheumatic drugs; TNF: tumor 
necrosis factor; MTX: methotrexate.
Table 1: Baseline characteristics
 Nonresponse Loss of response  Adverse events
 A  B C
 (n = 49) (n = 75)  (n = 73) P
Female (%) 29 (59.2) 46 (75.3) 55 (75.3) 0.101
Age, years, mean (SD) 54 (12) 55 (12) 55 (12) 0.970
Disease duration, 
years, median (range) 
6 (0.7-37) 7 (1-55) 10 (0.5-46) 0.074
RF-positive (%) 41 (83.7) 56 (74.7) 54 (74) 0.405
No. previous DMARD, 
median (range)* 
3 (2-10) 3 (1-8) 4 (1-9) 0.463
DAS28 at baseline 2nd 
anti-TNF agent, mean (SD) 
5.8 (1.1) 4.9 (1.1) 4.8 (1.3) <0.0001
1st anti-TNF agent used    
Infliximab (%) 18 (36.7) 29 (38.7) 44 (60.3) 0.010
Etanercept (%) 16 (32.7) 27 (36.0) 12 (16.4) 0.021
Adalimumab (%) 15 (30.6) 19 (25.3) 17 (23.3) 0.657
2nd anti-TNF agent used    
Infliximab (%) 2 (4.1) 2 (2.7) 1 (1.4) 0.644
Etanercept (%) 30 (61.2) 34 (45.3) 45 (61.6) 0.086
Adalimumab (%) 17 (34.7) 39 (52) 27 (37) 0.086
Switch of therapy    
Antibody to receptor 
blocker (%) 
30 (61.2) 34 (45.3) 45 (61.6) 0.086
Receptor blocker to 
antibody (%) 
16 (32.7) 27 (36) 12 (16.4) 0.021
Antibody to antibody (%) 3 (6.1) 14 (18.7) 16 (22) 0.062
Concurrent medication 2nd anti-TNF agent used**  
MTX (%) 23 (46.9) 41 (54.7) 28 (38.4) 0.138
Other DMARD (%) 7 (14.3) 21 (28.0) 19 (26.0) 0.186
Corticosteroids (%) 28 (57.1) 27 (36) 16 (21.9) <0.0001
doc.blom.indd   91 27-11-12   15:01
92
nonresponders received oral corticosteroids more frequently as concomitant 
therapy than the other two groups (P < 0.0001). Patients who failed due to adverse 
events switched less frequently from a receptor blocker to a monoclonal antibody 
than the patients who failed due to loss of response (P = 0.007). 
 At 3 and 6 months, 4% (2/49) and 12% (6/49) of the nonresponders, 7% (5/75) 
and 21% (16/75) of patients who failed due to loss of response, and 11% (8/73) 
and 23% (17/73) of patients who failed due to adverse events had discontinued 
the second TNF blocking agent. Table 2 shows the reasons for discontinuation in 
these patients. These patients were not taken into account in the analyses of the 
effect of the second TNF blocking agent at these time points, according to the per-
protocol analysis.
* Patient’s own initiative. ** In group A 1 patient died and 1 patient discontinued due to planned 
surgery; in group B 1 patient discontinued because of wish for pregnancy; in group C 3 patients 
discontinued on their own initiative and 1 patient was lost to follow-up.
Table 2: Reasons for discontinuation of the second TNF blocking agent at 3 and 6 months 
and the total follow-up time
 Nonresponse Loss of response Adverse events
 A  B C
 (n = 49) (n = 75) (n = 73)
 3 months   
 Lack of effect (%) - 2/5 (40) 1/8 (13)
 Adverse events (%) 2/2 (100) 3/5 (60) 7/8 (88)
 Other (%) - - -
 6 months   
 Lack of effect (%) 4/6 (67) 10/16 (63) 4/17 (24)
 Adverse events (%) 2/6 (33) 6/16 (38) 12/17 (71)
 Other (%)* - - 1/17 (6)
 Total follow-up time   
 Lack of effect (%) 13/20 (65) 20/30 (67) 7/26 (27)
 Adverse events (%) 5/20 (25) 9/30 (30) 15/26 (58)
 Other (%)** 2/20 (10) 1/30 (3) 4/26 (15)
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Figure 1: Mean DAS28 (95%CI) during use of the first and second TNF blocking agent. 
Time to stopping the first TNF blocking agent: median 3 months (1-20) for the nonresponders,
12 months (3-62) for patients who failed due to loss of response, and 6 months (0-29) for patients who 
failed due to adverse events (p < 0.0001). *Significant compared to nonresponse. 
Effect of the second TNF blocking agent
Figure 1 shows the mean DAS28 at baseline, at 3 and 6 months, and at the time 
of discontinuation of the first TNF blocking agent, and at baseline and 3 and 6 
months of the second agent. At 3 and 6 months after the start of the second TNF 
blocking agent, the DAS28 did not differ between the three groups.
 Results of analyses of the primary and secondary outcomes are shown in Table 
3. At 6 months, the disease activity improved significantly in all three groups 
(between -0.6 and -1.3; P ≤ 0.005). After the correction for disease activity and 
use of corticosteroids at baseline, this improvement did not differ between the 
groups. Similar results were found for the DAS28 at 3 months. The response rates 
were also comparable between the three groups at 3 and 6 months. No differences 
were observed between the groups regarding the percentages of patients who 
reached a DAS28 ≤ 3.2. 
 Drug survival did not differ between the three groups (log rank: P = 0.630; 
Figure 2). By July 2006 (hospital register) and December 2007 (DREAM register), 
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Table 3: Effect of the second TNF blocking agent. Values are means (standard deviation) unless 
stated otherwise
 Nonresponse Loss of Adverse P P P
  response events A vs B A vs C B vs C
 A B C  
 (n = 49) (n = 75) (n = 73)
Primary outcome 	 	 	 	 	
Change	of	DAS28	
at	6	months		
-1.3	(1.3)	 -0.6	(1.3)	 -1.0	(1.4)	 0.965*	 0.219*	 0.173*
Secondary outcomes	 	 	 	 	 	
Change	of	DAS28	
at	3	months  
-1.2	(1.0)	 -0.7	(1.3)	 -0.8	(1.4)	 0.901*	 0.608*	 0.499*
Response at 3 months	 	 	 	 	 	
Good	(%)	 7/44	(16)	 3/38	(8)	 7/46	(15)	 0.269	 0.928	 0.302
Moderate	(%)	 18/44	(41)	 13/38	(34)	 14/46	(30)	 0.533	 0.299	 0.712
DAS28	≤	3.2	
at	3	months	(%)	
8/44	(18)	 7/44	(16)	 13/49	(27)	 0.777	 0.336	 0.213
Response at 6 months	 	 	 	 	 	
Good	(%)	 4/33	(12)	 7/41	(17)	 7/40	(18)	 0.552	 0.523	 0.959
Moderate	(%)	 18/33	(55)	 14/41	(34)	 14/40	(35)	 0.078	 0.094	 0.936
DAS	28	≤	3.2
at	6	months	≤	3.2	(%)	
5/33	(15)	 11/41	(27)	 11/43	(26)	 0.225	 0.269	 0.897
*Based on the multiple linear regression analyses in which the raw data were corrected for difference 
between the groups in DAS28 at baseline and use of corticosteroids. DAS28 was missing at baseline, at 
3 at 6 months of the second TNF blocking agent: in respectively 2% (1/49), 6% (3/47) and 23% (10/43) 
of A; in respectively 9% (7/75), 37% (26/70) and 32% (18/57) of B; and in respectively 12% (9/73), 25% 
(16/65) and 23% (13/56) of C. Improvement in DAS28 and response rates could not be calculated due 
to missing values at baseline and/or at 3 or 6 months: in respectively 6% (3/47) and 23% (10/43) of A; 
in respectively 46% (32/70) and 28% (16/57) of B; and in respectively 29% (19/65) and 29% (16/56) of C. 
DAS28: Disease Activity Score in 28 joints.
76 (39%) discontinued the second TNF blocking agent after a median duration of 
use of 5.1 months (0.1-33.3). Table 2 also shows the reasons for discontinuation 
for each group after the total follow-up period. Patients who discontinued the 
first TNF blocking agent due to nonresponse or loss of response discontinued 
the second TNF blocking agent more frequently due to lack of response; and 
patients who failed the first TNF blocking agent due to adverse events also failed 
the second more often due to adverse events (P = 0.003). 
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Discussion
Our aim was to investigate whether the reason for discontinuation of the first TNF 
blocking agent influences the effect of a second TNF blocking agent. The results 
showed improvement of the DAS28 at 6 months from baseline of -0.6 to -1.3 and 
response rates of 51% to 67%, without significant differences between patients 
who failed the first TNF blocking agent due to nonresponse, loss of response 
or adverse events. It is noteworthy, however, that the mean disease activity 
remained moderate during the study period in all groups. As well, the reason 
for discontinuation of the first TNF blocking agent was related to the reason for 
discontinuation of the second. However, overall, the results suggest that a second 
TNF blocking agent may be effective after failure of the first regardless of the 
reason for discontinuation of the first agent.
 Our observations on the effect of the second TNF blocking agent are comparable 
to those of previous studies in which it was concluded that a switch to a second 
agent can be effective (7-15). However, previous studies found conflicting results 
with regard to particular groups of patients who may benefit most from a switch 
Figure 2: Drug survival of the second TNF blocking agent.  
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to a second TNF blocking agent when classified by reason for discontinuation of 
the first agent (7). For instance, a higher response rate to etanercept was suggested 
in patients who were nonresponders to infliximab compared to the patients 
who discontinued due to loss of response (14). On the other hand, a switch to 
adalimumab after nonresponse with infliximab was shown to be less effective 
than a switch to adalimumab after failure due to loss of response (26). Further, 
the drug survival and EULAR response rate of the second TNF blocking agent 
were better in patients who discontinued the first agent due to adverse events 
than in those who switched due to lack of effect (12;27). However, when response 
was assessed by the ACR criteria, no differences were observed (27). Because of 
these conflicting results, no group of patients can be identified who may benefit 
most from a switch to a second TNF blocking agent classified by the reason for 
discontinuation of the first TNF blocking agent. This is confirmed by our results, 
as we found no differences in effect of the second TNF blocking agent among the 
three reasons for discontinuation of the first agent: nonresponse, loss of response, 
or adverse events. 
 In contrast to the findings that the effect of the second TNF blocking agent 
after failure of the first was similar among the three groups by reason for 
discontinuation, we observed that the reason for discontinuation of the first agent 
was related to the reason for discontinuation of the second. This is in agreement 
with the results of a previous study by Hyrich, et al (28). However, we emphasize 
that drug survival and reason for discontinuation may be influenced by many 
factors besides the actual effect of therapy, including availability of other drugs 
and patient and doctor preferences and expectancies. Therefore, we consider the 
results of the analyses on effect and response to therapy more valid. 
 In addition to the three reasons for discontinuation of first TNF blocking agent 
used in our study, Van Vollenhoven proposed a fourth reason: partial response 
(29). This group is defined as patients who showed only moderate response to 
the first TNF blocking agent, with continuing moderately active disease. In these 
patients, a switch to a second TNF blocking would be useful only if a low disease 
activity could be achieved. In our study, the patient group who failed due to loss of 
response was a combination of patients who actually failed due to loss of response 
and of partial responders. The power of our study was too limited to compare the 
outcome of a second TNF blocking agent between these two subgroups.
 This study had some limitations. First, the classification of the three groups by 
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reason for discontinuation of first TNF blocking agent was dependent on the main 
reason reported by the attending rheumatologist. If the reason to discontinue the 
first agents was “a combination of lack of effect and adverse events,” for our study 
patients were classified as “discontinuing because of lack of effect.” In this group 
of patients, neither of these two reasons was the major reason to discontinue, but 
merely a general dissatisfaction with the effect of therapy. We assume that adverse 
events were mild and acceptable until the time of discontinuation; otherwise 
patients would have discontinued treatment earlier due to the adverse events. 
The additional lack of effect was the reason patients eventually discontinued 
therapy. This was the case in 10% (5/49) of the patients who were classified as 
nonresponders, and in only 5% (4/75) of the patients who failed due to loss of 
response. Considering these low percentages, we assume that our conclusions 
were not influenced by misclassification. Further, the observational design of the 
study had advantages and disadvantages. The results closely reflect the effect of 
TNF blocking agents in daily clinical practice. On the other hand, the percentage 
of missing data is considerable. The most favourable study design to investigate 
the outcome of a switch between TNF blocking agents would be a randomized 
placebo-controlled trial directly comparing patients who switch to a second TNF 
blocking agent with patients who continue the first. However, such a trial would 
not be ethical, since continuing treatment in a patient who has shown adverse 
events or no response to therapy, would not be justifiable. 
 As noted in the introduction, there is no indication that HACA or HAHA 
formation during treatment with the first TNF blocking agent may influence the 
effect of a second agent (19). Although HACA and HAHA were not measured 
in our study, our results from epidemiological analyses seem to support this 
assumption. If the presence of HACA or HAHA influenced the effect of the 
second TNF blocking agent, no effect of the second TNF blocking agent would 
be expected. However, in patients who discontinued the first TNF blocking agent 
due to either lack of effect or adverse events, the second agent was effective. In 
addition, we hypothesized that differences in response to TNF blocking agents 
among RA patients could be related to genetic variation within the TNFA gene 
or other candidate genes within the TNF-α pathway, especially in those patients 
who failed the first TNF blocking agent due to primary nonresponse. Against 
our expectations, our data showed that a switch to a second TNF blocking agent 
was effective even in this group of patients. Since all three TNF blocking agents 
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currently available differ in biochemical structures and properties, it is therefore 
conceivable that genetic variation in the binding site of one of the agents may 
not influence the effect of another agent using another binding site (30-32). To 
investigate the effect of switching agents, it would be interesting to compare 
switching between a monoclonal antibody and a receptor blocker with the effect 
of switch between two monoclonal antibodies for each reason for discontinuation 
of the first TNF blocking agent. However, in our study, the patient numbers for 
each group were too limited for these analyses. 
 The goals of treatment in RA are to achieve remission, to prevent joint damage, 
and to maintain full function. In our study, only 15-27% of the patients achieved 
low disease activity (DAS28 ≤ 3.2) after 6 months of treatment with the second 
TNF blocking agent. The question rises whether a switch to a biological agent 
with another mechanism of action, such as B cell-depleting (rituximab) or 
costimulation-blocking therapy (abatacept), may be more effective in reaching 
these goals instead of a switch to a second TNF blocking agent. To date, there has 
been only one observational study looking into switching to rituximab versus 
switching to another TNF blocking agent. That study showed that switching to 
rituximab was more effective than switching to another TNF blocking agent (33). 
More research is needed to compare the various treatment options in patients 
who have failed TNF blocking therapy. 
 The results of our observational study suggest that a second TNF blocking agent 
may be effective after failure of the first regardless of the reason for discontinuation 
of the first. In daily clinical practice, the reason for discontinuation of the first 
TNF blocking agent therefore cannot be used to identify a group of patients who 
may benefit most, or who will not benefit, from a switch to a second TNF blocking 
agent after failure of the first TNF blocking agent. 
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Effectiveness of a third tumor necrosis factor-α (TNF) 
blocking agent compared with rituximab after failure of 
two TNF blocking agents in rheumatoid arthritis
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Abstract
Objective
To compare the effectiveness of a third tumor necrosis factor-α (TNF) blocking 
agent with rituximab after failure of two TNF blocking agents in patients with 
rheumatoid arthritis (RA) in daily clinical practice.
Methods
Patients receiving a third TNF blocking agent or rituximab after failure of two 
TNF blocking agents were selected from a Dutch biologic registry. The primary 
outcome was the results of the Disease Activity Score in 28 joints (DAS28) over 
the first 12 months after start of the third biological agent using mixed-model 
analyses. Secondary outcomes included the course of the Health Assessment 
Questionnaire (HAQ) and the separate components of the DAS28 over the first 
12 months and the change from baseline in DAS28 and HAQ at 3 and 6 months. 
Results
The overall course of the DAS28 over the first 12 months was significantly 
better for rituximab (P = 0.0044), as also observed for the HAQ, although the 
latter results were not statistically significant (P = 0.0537). The erythrocyte 
sedimentation rates, C-reactive protein, and swollen joint counts showed a better 
course for rituximab (P = 0.0008, P = 0.0287 and P = 0.0547, respectively), but 
not the tender joint counts or visual analogue scale for general health. DAS28 
decreased significantly in both groups at 3 and 6 months (P ≤ 0.024), but the 
change in HAQ was significant for rituximab only at 3 months (P = 0.009).
Conclusion
During the first 12 months of therapy, a larger improvement in disease activity and 
a trend towards a larger decrease in functional disability was observed in patients 
receiving rituximab. Switching to a biological agent with another mechanism of 
action might be more effective after failure of two TNF blocking agents in RA. 
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Introduction
Tumor necrosis factor-α (TNF) blocking therapy has been shown to be efficacious 
in the treatment of rheumatoid arthritis (RA), with response rates of about 70% 
in the active treatment group, as shown in large randomized controlled trials 
(RCTs) (1-3). However, some patients may fail this therapy due to lack of effect or 
adverse events. Switching to another TNF blocking agent can be beneficial after 
failure of a first TNF blocking agent (4-8), as applied in daily clinical practice. 
However, a second TNF blocking agent is not effective in all patients. After failure 
of a second TNF blocking agent, two treatment options remain: switch to a third 
TNF blocking agent or switch to a biological agent with another mechanism of 
action, for instance, B-cell depleting (rituximab) and costimulation-blocking 
therapies (abatacept). Evidence to support superiority of either option is lacking, 
as no randomized head-to-head comparison of these two treatment strategies has 
been conducted to date. 
 Recent publications suggest that switching to B-cell depleting therapy with 
rituximab might be more beneficial than switching to another TNF blocking agent 
after failure of at least one TNF blocking agent, especially after failure of previous 
TNF blocking therapy due to ineffectiveness (9;10). However, the follow-up times 
of these studies were short and observations after discontinuation of therapy or 
retreatment with rituximab were censored in the analyses. 
 Therefore the decision to switch to another biological agent or to start a third 
TNF blocking agent remains at the discretion of the treating physician and is 
not guided by evidence. We investigated which treatment strategy is most 
effective in daily clinical practice after failure of two TNF blocking agents. Since 
data regarding abatacept were limited in our study population (available in the 
Netherlands in daily clinical practice from October 2007), our objective was 
to compare the effectiveness of rituximab with the effectiveness of a third TNF 
blocking agent after failure of two TNF blocking agents in daily clinical practice. 
Methods
Patients
RA patients with failure of two TNF blocking agents who received either a third 
TNF blocking agent or rituximab with a follow-up of at least 12 months were 
selected from the Dutch RhEumatoid Arthritis Monitoring (DREAM) register. 
doc.blom.indd   107 27-11-12   15:01
108
This register includes RA patients who started treatment with biological agents 
for the first time in daily clinical practice, and began in 1997 in one hospital 
(Radboud University Nijmegen Medical Centre). Since February 2003, the 
register contains data from eleven hospitals (11). 
 All patients were at least 18 years of age and fulfilled the 1987 American 
College of Rheumatology criteria for RA at inclusion (12). They satisfied the 
Dutch criteria for reimbursement in TNF blocking therapy, i.e., moderate to high 
disease activity (Disease Activity Score in 28 joints [DAS28] ≥ 3.2) and failure of at 
least two disease-modifying antirheumatic drugs (DMARDs) including optimal 
doses of methotrexate (MTX; 25 mg per week, combined with folic acid). In the 
Netherlands, treatment with rituximab is allowed in patients who had failed at 
least one TNF blocking agent or if TNF blocking therapy was contraindicated. 
 The data collection protocol for the register was submitted to the ethics 
committee. Since the register contains data from daily clinical practice, the ethics 
committee determined that no ethical approval according to the Dutch law was 
required. 
Treatment
The choice of treatment and the dosing schemes were at the discretion of the 
attending rheumatologist. TNF blocking therapy was in general given following 
Dutch labeled doses: infliximab 3 mg/kg intravenously (IV) every 8 weeks after 
a loading dose at Weeks 0, 2 and 6; etanercept either 25 mg biweekly or 50 mg 
once weekly subcutaneously; or adalimumab 40 mg subcutaneously every other 
week. Rituximab was given as 2 infusions of 1000 mg with a 2-week interval. 
Patients received 50 or 100 mg methylprednisolone IV, 2 mg clemastine IV, and 
1000 mg oral acetaminophen as premedication to prevent adverse events during 
the infusions. Patients could receive a retreatment with rituximab according to 
the international consensus statement, which advises retreating patients after at 
least 24 weeks in case of increasing disease activity after initial clinical response or 
in responders who have considerable residual disease activity (DAS28 > 3.2) (13).
TNF blocking therapy or rituximab could be combined with DMARDs and/
or corticosteroids. Start and stop dates of the TNF blocking therapy, rituximab, 
DMARDs and corticosteroids, doses, and reasons for changes were recorded. 
Retreatment with rituximab was recorded. Unlike other biological agents, it is 
difficult to define an exact stop date for rituximab. The patients who started a new 
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DMARD or biological agent after 3 months of initiation of rituximab therapy 
and who were not retreated with rituximab, were considered as patients who 
discontinued rituximab therapy. 
Outcome measures
Baseline characteristics were recorded, including age, sex, disease duration, 
number of previous DMARDs, and rheumatoid factor (RF) status. Patients were 
assessed at the start of TNF blocking therapy or rituximab and every 3 months 
thereafter. Assessments included tender (TJC) and swollen joint counts (SJC), 
erythrocyte sedimentation rates (ESR), C-reactive protein (CRP) levels, and the 
visual analogue scale for general health (VASGH). The DAS28 was calculated to 
evaluate disease activity (14). If the DAS28 was missing because of a missing value 
for ESR, the ESR was imputed by linear multivariate regression using the patient’s 
values for TJC, SJC, and VASGH. Response was defined as good and/or moderate 
using the European League Against Rheumatology (EULAR) response criteria 
(15). Functional disability was assessed by the Health Assessment Questionnaire 
(HAQ) (16;17). 
 
Analyses
Data of the first 12 months after start of the third TNF blocking agent or 
rituximab were used. Analyses were on an intention-to-treat (ITT) basis: patients 
were analysed in the treatment group in which they first started, irrespective of 
whether they discontinued or continued this treatment during the first 12 months 
of follow-up. Such an ITT was possible to perform because data collection was 
continued when patients had stopped using their initial therapy. 
 Baseline characteristics were expressed as mean (± SD) or as median (interquartile 
range) values as appropriate and compared between the two treatment groups using 
the Pearson’s chi-squared test for categorical data and the unpaired Student’s t test 
or the nonparametric Mann-Whitney U test for continuous data. A description 
was given of the treatments during the first 12 months of follow-up after start of 
the third TNF blocking agent or rituximab. The percentage of patients receiving 
rituximab who received a retreatment was described. If patients discontinued 
therapy, the reason for discontinuation was given. 
 The primary outcome was the course of the DAS28 over the first 12 months 
of follow-up. The secondary outcomes were the course of the HAQ and the 
doc.blom.indd   109 27-11-12   15:01
110
separate components of the DAS28 (SJC, TJC, VASGH, ESR, and CRP) over 
the first 12 months of follow-up. We used a mixed model to accommodate the 
dependencies caused by repeated measurements. After evaluating several error 
structures, we found that a compound symmetry error structure gave the best fit. 
The independent variables in the full model were treatment, follow-up time, the 
square of follow-up time, and the interactions between treatment and follow-up 
time, and treatment and the square of follow-up time. In the restricted model 
the interaction terms were dropped. Since maximum likelihood was used as 
estimation criterion, we used a likelihood ratio test to evaluate whether the full 
model gave a superior fit, thus indicating that the development over time was 
different in the two treatment conditions.
 To check for possible confounding factors, we tested whether known predictors 
for treatment outcomes were different between the two treatment groups, such 
as sex, age, disease duration, RF status, concomitant DMARD use, and number 
of previous DMARDs. Univariate analyses showed that none of these factors was 
different between the two treatment conditions. 
 Posthoc, the changes from baseline in DAS28, HAQ, and the separate 
components of the DAS28 at 3 and at 6 months within the groups were analysed 
by paired Student’s t test. The response rates and percentages of patients who 
achieved a DAS28 score of ≤ 3.2 at 3 and 6 months were described. P values < 
0.05 were considered significant. Analyses were performed using SPSS version 
17.0 (SPSS Inc., Chicago, IL, USA). 
Results
Baseline characteristics
In total, 64 patients with RA received a third TNF blocking agent and 90 
received rituximab after failure of two TNF blocking agents prior to July 2010. 
Table 1 shows the baseline characteristics. Except for a higher ESR value in the 
patients receiving rituximab (P = 0.049), there were no differences in baseline 
characteristics between the two treatment groups.  
 In both groups, most patients had failed a monoclonal antibody (infliximab or 
adalimumab) and a soluble receptor (etanercept): 80% in the rituximab group 
and 66% in the third TNF blocking agent group, respectively. 
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Treatment during the first 12 months of follow-up
Figure 1 describes the therapies patients received during the first 12 months after 
start of the third TNF blocking agent or rituximab. Of the patients receiving a third 
TNF blocking agent, 48% (31/64) still received this treatment up to 12 months. 
On the other hand, 52% (33/64) of the patients had discontinued therapy. The 
reason for discontinuation was ineffectiveness in 45% (15/33), adverse events in 
42% (14/33) and other reasons in 12% (4/33). 
 In the rituximab group, 88% (79/90) continued therapy up to 12 months. Of 
these patients, 54% (43/79) received a retreatment with rituximab. The median 
time to retreatment was 8.3 months (interquartile range 3.3). In 12% (11/90) of 
the patients, rituximab therapy was discontinued at 12 months. The main reason 
for discontinuation in this group was ineffectiveness, in 91% (10/11). One patient 
discontinued because of adverse events. 
Effectiveness on disease activity and functional disability
Figure 2A shows the mean DAS28 (95%CI) at baseline and 3, 6, 9, and 12 months. 
At 6 months, the mean DAS28 was significantly lower in the rituximab patients 
(3.91 [SD 1.25] vs 4.54 [SD 1.40], P = 0.021). Longitudinal analyses showed that 
the course of the DAS28 over the first 12 months was significantly better in the 
rituximab patients (P = 0.0044). In the patients receiving rituximab, the DAS28 
showed a slight increase from a mean of 3.9 (SD 1.3) at 6 months to a mean of 4.2 
(SD 1.4) at 12 months, which was not significant (P = 0.140).
 Figure 2B shows the mean HAQ over the first 12 months of follow-up. There 
was a trend to a better course of the HAQ over the first 12 months in the rituximab 
group, although longitudinal analyses showed a borderline significance (P = 
0.0537). The course of the separate components of the DAS28 over time (baseline, 
3, 6, 9, and 12 months) showed a pattern similar to the course of the DAS28 over 
the same period, with an initial decrease up to 6 months and a slight increase 
thereafter in the rituximab group (data not shown). Longitudinal analyses of 
the separate components of the DAS28 showed that the course over the first 12 
months of follow-up was better in the rituximab patients for the ESR and CRP (P 
= 0.0008 and P = 0.0287, respectively). For SJC, the analyses showed a borderline 
significance (P = 0.0547) in favour of the rituximab group. No difference was 
observed between the two treatment groups for the TJC and VASGH (P = 0.1764, 
P = 0.348, respectively). 
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Table 1: Baseline characteristics
 Third TNF   
 blocking agent Rituximab
 (n = 64) (n = 90) P
Female (%) 46/64 (72) 66/90 (73) ns
Age, years, mean (SD) 53.3 (12.9) 56.6 (12.2) ns
Disease duration, years, 
median (IQR) 
8.9 (9.2) 10.9 (13.7) ns
Reumatoid factor-positive (%) 51/64 (80) 69/90 (77) ns
No. previous DMARDs, 
median (IQR) 
4.0 (2.0) 4.0 (2.3) ns
DAS28, mean (SD)* 5.1 (1.30) 5.32 (1.25) ns
SJC28, mean (SD) 9.4 (6.5) 8.7 (5.8) ns
TJC28, mean (SD) 9.0 (7.5) 8.0 (6.3) ns
ESR, mm/hour, median (IQR) 26.0 (29.5) 31.0 (28.5) 0.049
CRP, mg/l, median (IQR) 10.0 (24.5) 16.0 (38.0) ns
VASGH, mean (SD) 57.5 (26.9) 60.8 (19.1) ns
HAQ, mean (SD)** 1.51 (0.64) 1.52 (0.78) ns
First TNF blocking agent   
Infliximab (%) 31 (48) 38 (42) ns
Etanercept (%) 9 (14) 32 (36) 0.003
Adalimumab (%) 24 (38) 20 (22) 0.039
Second TNF blocking agent   
Infliximab (%) 12 (19) 6 (7) 0.021
Etanercept (%) 33 (52) 40 (44) ns
Adalimumab (%) 19 (29) 44 (49) 0.017
Third TNF blocking agent   
Infliximab (%) 21 (33)  
Etanercept (%) 22 (34)  
Adalimumab (%) 21 (33)  
Concomitant therapy   
MTX (%)     34/64 (53) 42/86 (49) ns
Other DMARDs (%) 20/64 (31) 19/86 (22) ns
Oral corticosteroids (%) 24/64 (38) 38/86 (44) ns
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* DAS28, SJC28, TJC28, and ESR were missing in 17% (11/64), CRP was missing in 23% (15/64), and 
VASGH was missing in 36% (23/64) of patients receiving a third TNF blocking agent. DAS28, SJC28, 
TJC28, and ESR were missing in 10% (9/90), CRP was missing in 12% (11/90), and VASGH was missing 
in 12% (11/90) of patients receiving rituximab. ** Missing in 34% (22/64) of patients receiving a third 
TNF blocking agent and in 19% (17/90) of patients receiving rituximab. DMARD: disease-modifying 
antirheumatic drugs; IQR: interquartile range; DAS28: Disease Activity Score in 28 joints; SJC: swollen 
joint count; TJC: tender joint count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; VASGH: 
visual analogue scale for general health; HAQ: Health Assessment Questionnaire; TNF: tumor necrosis 
factor; MTX: methotrexate; ns: not significant.
 Posthoc analyses showed that the improvement in disease activity was 
statistically significant at 3 and 6 months in contrast to baseline within both 
treatment groups. At 3 months this change was -1.01 (SD 1.55, P = 0.001) in the 
patients receiving a third TNF blocking agents and -1.35 (SD 1.18, P < 0.0001) in 
the patients receiving rituximab. At 6 months the change in DAS28 from baseline 
was -0.58 (SD 1.87, P = 0.024) in the patients receiving a third TNF blocking 
agent and -1.39 (SD 1.31, P < 0.0001) in the patients receiving rituximab. The 
change from baseline in the HAQ was only significant in the rituximab patients 
at 3 months (-0.23 [SD 0.63], P = 0.009), but not at 6 months (-0.17 [SD 0.58], 
P = 0.053). In the patients receiving a third TNF blocking agent no significant 
improvement of the HAQ was observed at 3 and at 6 months (-0.17 [SD 0.47], 
P = 0.070, and 0.09 [SD 0.46], P = 0.309, respectively). At 3 months and at 6 
months, all separate components of the DAS28 improved significantly within the 
rituximab group (P ≤ 0.007). However, within the patients receiving a third TNF 
blocking agent, only the TJC and SJC improved significantly at 3 months (P = 
0.045, P = 0.013, respectively) and only the SJC at 6 months (P = 0.034). At 3 
months, 60.6% (20/33) of the patients receiving a third TNF blocking agent and 
69.2% (45/65) of the patients receiving rituximab reached a moderate or good 
EULAR response. At 6 months, these percentages were 48.4% (15/31) and 67.2% 
(45/67), respectively. The percentage of patients with a DAS28 ≤ 3.2 at 3 and at 6 
months in the group receiving a third TNF blocking agent was 16.2% (6/37) and 
18.4% (6/35), respectively. In the rituximab patients, at 3 months 30.4% (21/69) 
and at 6 months 29.0% (20/69) reached a DAS28 ≤ 3.2.   
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Discussion
The effectiveness of a third TNF blocking agent was compared with the 
effectiveness of rituximab after failure of two TNF blocking agents in patients 
with RA using observational data from daily clinical practice. In patients 
receiving rituximab, the overall course of disease activity was better than in the 
patients receiving a third TNF blocking agent during the first 12 months. As 
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Figure 1: Description of the therapies patients received during the first 12 months after start of the third 
TNF blocking agent (A) or rituximab (B) after failure of two TNF blocking agents.
Other = no new treatment started, continuation of concomitant DMARD therapy, or information about 
new treatment is missing.
Figure 2: The mean DAS28 (A) and the mean HAQ (B) with 95% confidence intervals (95%CI) over the 
first 12 months.
*= significantly different
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well, functional disability was lower in the rituximab group, although this did 
not reach statistical significance. Analyses of the separate components of the 
DAS28 showed a statistically significant better course of the ESR and CRP in 
the rituximab patients, a borderline significant better course of the SJC, but no 
difference in TJC and VASGH between the two treatment groups.
 The improvement in disease activity in patients receiving a TNF blocking 
agent or rituximab was comparable at 6 months after treatment initiation both 
in our study and a previous study (9). Notably, we observed a slight increase 
in disease activity from 6 up to 12 months in the patients receiving rituximab; 
this was not seen during the 9 months of follow-up in the study of Finckh, et al 
(9). In a RCT, however, a further decline in disease activity was observed when 
patients were retreated with rituximab during the follow-up (18). According to 
the international consensus statement (13), the Dutch guideline for rituximab 
therapy in RA advises consideration of retreatment with rituximab after at least 
24 weeks in cases of increasing disease activity after initial clinical response, or 
in responders who have considerable residual disease activity (DAS28 > 3.2). The 
exact timing of retreatment in our study was at the discretion of the attending 
rheumatologist. The increase in disease activity may therefore have been caused by 
a delay among the timing of indication for retreatment, the decision to prescribe 
a second course by the treating rheumatologist, and the time needed to achieve 
effect again after retreatment. A previous study also observed some increase 
in disease activity in the majority of patients before retreatment. Retreatment 
resulted in a response rate similar to the previous courses in most patients (19). 
The follow-up period of our study was too short to determine the effectiveness 
of retreatment of rituximab. Further research is therefore indicated to investigate 
the timing of retreatment with rituximab in order to prevent large fluctuations in 
disease activity in individual patients in daily clinical practice, balanced against 
potential overdosing with accompanying high costs and possible side effects.    
 We evaluated only the effectiveness of rituximab therapy compared to a third 
TNF blocking agent after failure of two TNF blocking agents. It would also be 
interesting to compare the effectiveness of rituximab with TNF blocking therapy 
earlier in the treatment strategy of RA, for example after failure of one TNF 
blocking agent or in patients who are naive for TNF blocking agents. In our 
cohort, the data of these groups of patients are limited, because in our cohort 
most patients to date received rituximab after failure of two TNF blocking agents. 
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 The advantage of the observational design of our study is that the results reflect 
the effectiveness of TNF blocking therapy or rituximab in daily clinical practice, 
including the effects of a decision about when to retreat patients with rituximab. 
However, an important limitation of using such data is the risk for confounding by 
indication. Univariate analyses of the baseline characteristics showed only a higher 
ESR in the patients using rituximab, which might indicate that patients receiving 
rituximab had more active disease. A rheumatologist might be more inclined to 
start a biological agent with another mechanism of action in such patients after 
failure of previous TNF blocking therapy instead of switching to another TNF 
blocking agent. However, since the other baseline characteristics did not differ 
between the two treatment groups, we assume that there was no selection by 
patients of which biological agent they received as the third treatment. Therefore, 
a RCT directly comparing the effectiveness of TNF blocking therapy with the 
effectiveness of rituximab is indicated to provide a sound answer to this relevant 
research question. Other limitations of this observational study are the relative 
low numbers of patients and the high number of missing data. Since the literature 
shows that analysing only complete data results in more bias than imputation of 
missing data (20), we imputed the ESR by means of linear multivariate regression 
if this value was missing to calculate the DAS28. As well, longitudinal analyses 
using linear mixed models provide more power with small numbers of patients 
(21) and account for missing data better, since the analyses can handle inter-
individual differences in time intervals between measurement points. In our study, 
patients received TNF blocking agents following Dutch labeled doses. We are 
aware that in other countries other guidelines for treatment with biological agents 
might be present. One could assume that, if higher dosages had been provided, a 
third TNF blocking agent would have shown better effectiveness. However, in a 
previous study the effectiveness of a dose increase of TNF blocking therapy was 
limited (22). Therefore, our results are only generalizable to a situation in which 
more or less the same guidelines are present as in the Netherlands.
 These results from daily clinical practice show a larger improvement in disease 
activity and a trend towards a larger decrease in functional disability in patients 
receiving rituximab after failure of two TNF blocking agents during the first 12 
months of treatment compared to patients who receive a third TNF blocking agent. 
These results might indicate that switching to a biological agent with another 
mechanism of action, such as rituximab, can be more effective than switching to 
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a third TNF blocking agent after failure of two TNF blocking agents. However, a 
slight increase in disease activity was observed in the patients receiving rituximab 
from 6 up to 12 months, which may indicate the need for an earlier retreatment. 
Further research is needed not only to compare the effectiveness of TNF blocking 
therapy with the effectiveness of rituximab in a randomized clinical trial, but 
also to investigate when to retreat patients with RA receiving rituximab in daily 
clinical practice in order to maintain effectiveness of therapy. 
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Chapter 7
Research into established rheumatoid arthritis (RA) is important but 
challenging
Most of the patients seen by rheumatologists in daily clinical practice have 
established RA (1). The exact proportion depends on the definition used for 
established RA and the latter has been subject to change over the years. According 
to the Oxford English Dictionary the verb ‘to establish’ means ‘to set up on a firm 
or permanent basis’. There is general agreement that patients with established RA 
should meet the 1987 American College of Rheumatology (ACR) classification 
criteria for RA (2). Moreover, the definition of established RA depends also on 
that of early RA. Over the past years, the maximum disease duration for early 
RA has shifted from seven years to as low as one year to even 6 months in 
more recent studies (3;4). Regardless of the disease duration, other factors such 
as the presence of joint damage or failure to one or more disease-modifying 
antirheumatic drugs (DMARDs), might also distinguish established from early 
RA. As a result, patients with established RA are a very heterogeneous group with 
variable disease duration, degree of joint damage and disability. It is important 
to provide optimal treatment strategies which prevent joint damage progression 
and subsequent disability in patients with established RA, and research into 
this field is needed. The more since it seems plausible that the effect of therapy 
might be less pronounced than in early RA due to for instance the presence of 
irreversible erosive joint damage, osteoarthritis and other co-morbidities. In 
addition, patients with established RA have refractory disease with failure to 
previous DMARDs and/or biological response modifiers (biological agents) due 
to ineffectiveness or side effects, caused by for instance antibody formation (5-7) 
or occurrence of drug resistance (8). The patient’s and doctor’s preferences and 
experiences with previous therapies may also influence the choice of therapies for 
established RA. As a result of these factors, research into established RA is likely 
to be more complicated than into early RA, but even more challenging. 
Established RA in the future 
In the upcoming years, the characteristics of established RA will probably change 
due to the effectiveness of intensive treatment strategies currently used in early 
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RA (9-11). Over the last decades, the treatment guidelines for early RA have been 
rigorously changed. Up till the 90’s, only a couple of DMARDs and corticosteroids 
were available, and rheumatologists were reluctant to start these agents because of 
possible serious side effects, the fear of running out of treatment options, and the 
idea that RA was not such a destructive and disabling disease (12). Later research 
showed that serious joint damage might already occur in the first years of disease 
(13;14) which led to a trend towards earlier and more intensive treatment. In the 
last two decades, new therapies including biological agents became available and 
these have proven to prevent joint damage successfully (15-21). Data from the 
Nijmegen early RA Inception cohort (22) from 1989 onwards showed that the use 
of methotrexate (MTX) increased to 62% and the use of biological agents to 22% 
in 2008. This resulted in lower disease activity and less disability (23). In this same 
cohort, the prevalence of cervical spine damage due to RA was 16% after 9 years 
of follow-up (Chapter 3). This prevalence is considerably lower than those found 
in previous studies conducted between the 1960s and the 1980s with a prevalence 
up to 86% (24-26), especially if we consider that our study described patients 
in the pre-biological era (up to 2002). It is to be expected that the prevalence of 
cervical spine damage due to RA will further decline with the use of intensified 
treatment strategies in early RA.
 The current Dutch treatment guidelines (27) for early RA recommend to start 
with a traditional DMARD, preferably MTX, for at least 3 months in an adequate 
dosage. If this does not result in low disease activity (DAS28 < 3.2), switching to 
or adding another DMARD and/or biological agent should be considered. The 
choice should be based on the presence of risk factors for more disabling disease, 
such as rheumatoid factor (RF) or anti-cyclic citrulinated peptide antibody (anti-
CCP) positivity, high disease activity and joint damage. 
 At this moment, there are no guidelines for the treatment of established RA, 
but in daily clinical practice, after failure of several DMARDs, other options 
including biological agents can be considered. This scenario will surely change in 
the future, since biological agents are more and more used earlier in the disease 
course. As a result, in patients with established RA who have already failed one or 
more biological agents, further choices and possibilities in treatment options will 
become more limited. Besides, despite early and intensive therapy erosive joint 
damage cannot be fully prevented in early RA (28-30). Future expectations are 
that rheumatologists will still be confronted with erosive and disabling established 
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RA in their daily clinical practice. This group of patients should therefore be the 
focus of interest for further investigations.  
The effect of biological agents in established RA in daily clinical practice
Large randomized controlled trials (RCTs) have shown that biological agents 
combined with MTX can be effective in patients with established RA who failed 
to previous therapy with DMARDs and/or tumor necrosis factor-α (TNF) 
blocking agents (15-19;31). It has been shown that the effect of biological therapy 
in daily clinical practice is smaller than that observed in RCTs (32). RCTs make 
use of strict inclusion criteria in order to minimize the heterogeneity of the study 
population, to avoid bias and to increase internal validity of the study. However, 
only 21% to 79% of the RA patients from daily practice fulfil these criteria (32;33). 
Knowledge about the effect of treatment strategies in patients with established RA 
in daily clinical practice is therefore very important. In this thesis, we conducted 
several studies to provide evidence that support certain treatment options in daily 
practice using data from an observational cohort study.  
 In Chapter 4, we observed that dose increase was frequently applied in patients 
with lack of response or partial response to the initial dose of TNF blocking 
therapy in daily practice, especially in infliximab (36%), and to a lesser extent 
in adalimumab (12%) and etanercept (8%). These percentages are comparable 
with those observed in previous studies (34-36). However, the effectiveness of 
dose increase of TNF blocking agents after inadequate response is doubtful. 
Most previous studies have focused on infliximab. In patients who had a lack of 
response or a flare despite treatment with infliximab in a dose of 3 mg/kg every 
8 weeks, dose increase up to a maximum of 7.5 mg/kg every 8 weeks led to an 
improvement of ≥ 20% in the total tender and swollen joint count in > 80% of 
patients (37). Besides, a dose increase with one vial of 100 mg was shown to be 
effective in patients with a partial loss of response to the initial infliximab dosing 
scheme (38). In our study, the effect of dose increase of infliximab was however 
limited and similar results were observed for dose increase of adalimumab and 
etanercept (Chapter 4). These results were comparable with those found by two 
observational cohort studies and a randomized, double-blind study in which 
the effect of dose increase of infliximab was small (39;40), or not even better 
than continuing the initial dose after partial response (41). Only a few studies 
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investigated the effect of dose increase of adalimumab, also reporting conflicting 
results. One study showed a minimal effect of dose increase of adalimumab to 
weekly dosing of 40 mg on the  American College of Rheumatology (ACR) 20 
response criteria and ACR50 response criteria after lack of response or loss of 
response to the initial dose of 40 mg every 2 weeks (42). In a very small study in 
7 nonresponders to adalimumab, dose increase led to a mean ± SD decrease in 
DAS28 of 1.7 ± 1.2 (6). To our knowledge, no studies except ours are available 
evaluating the effect of dose increase in etanercept. Based on our and previous 
studies and the knowledge that switch to a second TNF blocking agent has proven 
to be effective after failure of the first (Chapter 5, (43-50)), we recommend to 
consider other treatment options such as switch to another TNF blocking agent 
or biological agent with another mechanism of action in patients who fail to 
respond to the first TNF blocking agent instead of increasing the initial dose. 
 We hypothesized that the reason for discontinuation of a TNF blocking agent 
might reflect the underlying mechanism of failure. Lack of response can be 
caused by genetic variance in the TNFA gene or other candidate genes in the 
TNF-pathway (51;52). In these patients switch to a second TNF blocking agent 
might be not effective as well. Loss of response or adverse events can be caused 
by the formation of human anti-chimeric antibodies (HACAs) or human anti-
human antibodies (HAHAs). However, there are no suggestions that these 
antibodies influence the effect of a second TNF blocking agent (5;7;53). The 
reason for discontinuation might therefore be used to predict the response to 
a second TNF blocking agent, in order to identify patients in whom switch to a 
second TNF blocking can be effective and those in whom for example a biological 
agent with another mechanism of action should be considered. This assumption 
was supported by previous studies in which for instance a somewhat higher 
ACR response to etanercept was found after lack of response compared to loss 
of response to infliximab (49). On the other hand, adalimumab after lack of 
response to infliximab was shown to be less effective than after loss of response 
(54). Further, the drug survival and European League Against Rheumatism 
(EULAR) response rate of a second TNF blocking agent were better after failure 
of the first due to adverse events than due to lack of effect (47;55). However, when 
response was assessed by the ACR criteria, no differences were observed (55). In 
our study (Chapter 5), we observed that a second TNF blocking agent might be 
effective after failure of the first, regardless of the reason for discontinuation. Due 
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to small patient numbers, we were not able to analyse the effect of switch between 
a monoclonal antibody and a receptor blocking agent or between two monoclonal 
antibodies by reason for discontinuation of the first. It would be interesting 
to investigate such comparison in a RCT. In addition, the effect of switch to a 
biological agent with another mechanism of action compared to a second TNF 
blocking agent by reason for discontinuation could be included in such RCT to 
identify patients in whom a biological agent with another mechanism of action 
would be more effective.
 To date, no direct head-to-head comparison has been conducted between 
different biological agents after failure of previous TNF blocking therapy. Two 
meta-analyses using data from randomized, placebo-controlled double-blind 
trials in established RA showed no differences in effect of abatacept, tocilizumab, 
rituximab and golimumab after inadequate response to TNF blocking therapy 
(56;57). The question is whether these results might be translated to daily clinical 
practice. In Chapter 6, we compared the effectiveness of a third TNF blocking 
agent with the effectiveness of rituximab after failure of two TNF blocking agents 
using observational data from daily practice. Patients who received rituximab 
showed a larger improvement of disease activity compared to those receiving 
a third TNF blocking agent. These results were in line with previous research 
(58;59), although in those studies, rituximab was already given after failure of the 
first TNF blocking agent. Our findings support the recommendation to consider 
a biological agent with another mechanism of action, such as rituximab, after 
failure of two TNF blocking agents. 
 
Which study design is appropriate for research into established RA?
The results of the studies in this thesis do not only give answers, but also raise a 
lot of additional questions. For instance, ‘would it be better to start a biological 
agent with another mechanism of action early in the disease, for example already 
after failure of the first TNF blocking agent?’; ‘what is the effect of other biological 
agents such as abatacept or tocilizumab in these patients?’; or ‘is it possible to 
predict which patient will benefit most from which biological therapy?’ These 
questions underline the need for further research into established RA. However, 
which study design is appropriate for such research?
 RCTs or systematic reviews combining RCTs are considered to provide the 
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highest grade of evidence for effect of treatment. Advantages of RCTs include 
homogeneous patient population and randomization to maximize internal 
validity; disadvantages are however the high costs and time-consuming 
procedures in these studies. Furthermore, serious side effects of a treatment can 
be missed because mostly a limited time period and selected groups of patients 
are studied. Moreover, the translation of results from RCTs to the heterogeneous 
group of patients with established RA in daily practice may be unreliable (32;33).
 An observational study design, as used in this thesis, might be a better option to 
investigate the effect and safety of therapy over a long period of time, because data 
from this design might reflect daily clinical practice more closely than that of a 
RCT. However, the observational study design cannot control for the distribution 
of subjects between treatment groups or for the doctor’s inclination to prescribe 
a specific treatment in patients with certain characteristics. This can lead to 
selection bias and confounding by indication. Furthermore, observational studies 
might over or underestimate treatment effects. Two previous studies using large 
biological registers showed that patients potentially eligible for RCTs with TNF 
blocking agents achieved similar ACR20 response percentages to those found 
in RCTs. Among ineligible patients, the ACR20 responses were lower, though 
their absolute improvement in disease activity was similar to the eligible patients. 
Important differences between eligible and ineligible patients were that ineligible 
patients had lower disease activity at baseline, more co-morbidities and lower 
functional status (32;33). Other researchers have shown that observational studies 
do not systematically overestimate the magnitude of treatment effects compared 
with those in RCTs (60;61). Furthermore, long-term prospective observational 
cohort-studies might reveal interesting findings which would have never been 
observed during RCTs with a limited study duration, for instance prognostic 
factors which can be easily used in daily clinical practice (62).
 Several guidelines have now been developed to improve quality and to allow 
comparison between observational studies in different registers (63;64). The 
EULAR formulated points to consider when establishing a biological register 
especially concerning safety data, but these points are also applicable for 
observational studies regarding effect of therapy. In this thesis, we used data 
from two large observational cohort studies: the Nijmegen Inception cohort (22) 
and the Dutch RhEumatoid Arthritis Monitoring (DREAM) register (65). Both 
observational cohorts fulfil these recommendations, with a clear defined aim of 
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the register, target population, which data to be collected and the data collection 
process, follow-up methods and ethical and legal considerations (22;65;66). 
 A direct head-to-head comparison using a RCT design would be the ideal 
study for evaluating the effectiveness of different biological agents after failure 
of previous DMARDs or biological agents, including TNF blocking agents 
and biological agents with another mechanism of action, such as rituixmab, 
abatacept and tocilizumab. However, due to the numerous possible treatment 
combinations, a very large study population is needed. Such study would be very 
time-consuming and costly. We therefore assent to the idea that observational 
studies aiming at monitoring therapy effect and safety in established RA are not 
only feasible, but also a valuable addition to RCTs. Results from such studies, as 
presented in this thesis, might be used to formulate new hypotheses for future 
research. 
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Chapter 8
Rheumatoid arthritis (RA) is a heterogeneous disease with an unpredictable 
course varying from mild to very disabling. In recent years, extensive research 
has been performed aimed at finding treatment strategies which are able to 
suppress or control the disease process in an early stage. However, most of the 
patients seen by rheumatologists in daily clinical practice have a longstanding 
or established disease. To date, research into the management of patients with 
established RA has been rather limited and hampered by the heterogeneity of this 
patient group. The effectiveness of therapy in established RA might be less than in 
early RA, for instance due to irreversible erosive joint damage, refractory disease, 
osteoarthritis, old age and co-morbidities. The objectives of this thesis were to 
explore the long-term consequences of established RA, and to investigate possible 
treatment strategies in these patients, using observational data from daily clinical 
practice.
 In Chapter 2, an overview was given of what is known from the literature on 
the clinical manifestations and long-term consequences of established RA, the 
possible treatment strategies, the role of prognostic factors, and the possibilities 
to measure disease outcome. 
 Next, we performed a descriptive study on the prevalence of cervical spine 
damage in a large observational Dutch inception cohort of patients with early RA 
with a follow-up of at least 6 to 12 years (Chapter 3). The prevalence of RA-related 
cervical spine damage was 16% at 9 years follow-up. Noteworthy, damage could 
be already present within the first 6 years of disease course and was associated 
with erosive disease of hands and feet. Patients without erosive disease 3 years 
after disease onset were unlikely to develop cervical spine damage within the first 
9 years. In these patients, cervical spine radiographs are only indicated if signs 
or symptoms for spinal cord compression are present. In patients with erosive 
damage of the hands and feet, rheumatologists should be aware of the possibility 
of cervical spine damage due to RA especially prior to anaesthesia. 
 In Chapter 4 to 6, we investigated several treatment options in patients 
with established RA who failed to respond to previous treatment with tumor 
necrosis factor-α (TNF) blocking agents, using observational data from the 
Dutch RhEumatoid Arthritis Monitoring (DREAM) register. The frequency and 
effectiveness of dose increase of adalimumab, etanercept and infliximab in the 
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treatment of patients with RA in daily clinical practice are described in Chapter 4. 
This study shows that the effectiveness of dose increase (frequently applied with 
infliximab, and less frequently with adalimumab and etanercept) was limited for 
all three agents. However, dose increase might be beneficial in nonresponders to 
the initial dosage, although the decrease in disease activity was moderate.  
 Chapter 5 describes the results of a study aimed to investigate whether the 
reason for discontinuation of the first TNF blocking agent influences the effect 
of a second TNF blocking agent. This study regarded the three main reasons for 
discontinuation of TNF blocking therapy: initial nonresponse, loss of response, 
and adverse events. It was shown that switching to a second TNF blocking agent 
might be effective, regardless of the reason for discontinuation of the first agent. 
The reason for discontinuation of the first TNF blocking agent cannot be used 
to identify those patients who might benefit most from switch to a second TNF 
blocking agent after failure of the first.
 In Chapter 6, we indirectly compared the effectiveness of a third TNF blocking 
agent with that of rituximab after a previous failure of two TNF blocking agents 
during a period of 12 months in daily clinical practice. In this setting, treatment 
with rituximab resulted in a larger improvement in disease activity and in a trend 
towards a larger decrease in functional disability. These results suggest that after 
failure of two previous TNF blocking agents a switch to a biological response 
modifying agent with a different mechanism of action, in our case rituximab, may 
be more effective than a third TNF blocking agent. Notably, we observed a slight 
increase in disease activity in the patients receiving rituximab from 6 up to 12 
months, which might indicate the need for an earlier retreatment in this group.  
 Observational studies as those presented in this thesis closely reflect the effect 
and outcome of therapy in patients with established RA in daily clinical practice 
and are therefore a valuable addition to randomized controlled trials. These studies 
might help to take decisions in the management of patients with established RA in 
daily clinical practice. In addition, they can be used to formulate new hypotheses 
for further research.       
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Chapter 9
Reumatoïde artritis (RA) is een chronische ziekte waarbij gewrichtsontstekingen 
op de voorgrond staan. De oorzaak van de ziekte is nog niet bekend. RA komt 
bij ongeveer 1% van de bevolking voor en twee keer zo vaak bij vrouwen als 
bij mannen. Als gevolg van ontsteking aan de gewichten kan blijvende schade 
aan kraakbeen en bot ontstaan. Dit worden erosies genoemd en deze kunnen 
uiteindelijk leiden tot ernstige standsafwijkingen (deformaties) van de gewrichten. 
Gewrichtsontstekingen en schade veroorzaken pijn en leiden samen met 
vermoeidheid tot verminderd functioneren in het dagelijks leven. RA is nog 
niet te genezen en patiënten hebben levenslang medicamenteuze en niet-
medicamenteuze behandeling nodig. 
 In de afgelopen jaren is er vooral onderzoek verricht naar het vinden van 
behandelstrategieën om gewrichtsontstekingen zo vroeg mogelijk in de ziekte te 
onderdrukken, gewrichtsschade te voorkomen en volledige functie te behouden. 
Deze behandeling bestaat voornamelijk uit het geven van zogenaamde ‘disease-
modifying antirheumatic drugs (DMARDs). Daarnaast zijn er biologische 
reumaremmers ontwikkeld, ook wel biologicals genoemd, die kunnen worden 
gegeven als behandeling met DMARDs onvoldoende effectief is. In tegenstelling 
tot de grote onderzoeken naar het effect van behandeling bij vroege RA, heeft het 
overgrote deel van de patiënten in de dagelijkse praktijk een al langer bestaande 
RA. Deze patiënten zijn meestal behandeld met meerdere verschillende DMARDs 
en soms ook biologicals. Ondanks die behandeling zijn er vaak nog pijnlijke 
en gezwollen gewrichten en is gewrichtsschade aanwezig. Onderzoek naar 
de behandeling van deze patiëntengroep is beperkt en wordt bemoeilijkt door 
de grote verscheidenheid binnen deze groep patiënten door de aanwezigheid 
van gewrichsschade, artrose en andere bijkomende ziekten. Het effect van 
de behandeling bij langer bestaande RA is hierdoor mogelijk ook minder 
uitgesproken dan bij vroege RA. 
 Het doel van dit proefschrift was daarom het beschrijven van de gevolgen van 
langer bestaande RA en het onderzoeken van mogelijke behandelstrategieën voor 
deze groep patiënten vooral gericht op de behandeling met biologicals. Voor de 
studies in dit proefschrift hebben we gebruik gemaakt van observationele data uit 
de dagelijks klinische praktijk. 
 Allereerst laat Hoofdstuk 2 een overzicht zien van wat er bekend is uit de literatuur 
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over het beloop van langer bestaande RA en de mogelijke behandelstrategieën. 
Ook wordt beschreven wat de rol is van prognostische factoren in het voorspellen 
van uitkomst van de ziekte en behandeling. Tot slot worden mogelijkheden 
besproken om het effect van behandeling en ziekte-uitkomst te meten. 
 Naast de gewrichten van de handen en voeten kunnen ook andere gewrichten 
worden aangetast door RA waaronder die van de nek, in medische terminologie 
de cervicale wervelkolom. Dit kan leiden tot ernstige neurologische klachten 
door aantasting van het ruggenmerg, zoals onder andere pijn in de nek, 
krachtsverlies en gevoelsstoornissen in armen en benen, en zelfs tot de dood 
als de hersenstam of het ruggenmerg beklemd raakt. Meestal geeft schade aan 
de cervicale wervelkolom echter weinig klachten. Daarbij komt dat patiënten 
met RA geregeld operaties moeten ondergaan vanwege de ziekte zelf, zoals 
orthopedische operaties, of bijkomende ziekten. Bij patiënten met instabiliteit 
van de cervicale wervelkolom bestaat er een kans dat door manipulatie van de 
nek voor de anesthesie of tijdens de operatie het ruggenmerg beklemd raakt met 
alle gevolgen van dien. Het is daarom van extra belang is om patiënten bij wie de 
kans op ernstige complicaties verhoogd is op tijd op te sporen. In Hoofdstuk 3 
hebben we een beschrijvende studie verricht naar het vóórkomen van cervicale 
wervelkolomschade als gevolg van RA in een groot observationeel cohort van 
patiënten met RA over een periode van minstens 6 tot 12 jaar. Uit dit onderzoek 
blijkt dat 16% van de patiënten schade heeft aan de cervicale wervelkolom 9 jaar 
na starten van de ziekte. Deze schade kon al aanwezig zijn binnen de eerste 6 jaar. 
Wij vonden daarnaast een relatie tussen schade aan de cervicale wervelkolom 
en de hoeveelheid erosieve schade aan de gewrichten van handen en voeten. Bij 
de patiënten die nog geen erosieve schade hadden 3 jaar na begin van de ziekte, 
zagen we geen schade aan de cervicale wervelkolom op 9 jaar. We kunnen daaruit 
concluderen dat bij deze patiënten het maken van röntgenfoto’s van de cervicale 
wervelkolom alleen geïndiceerd is bij klachten die zouden kunnen passen bij 
schade aan de cervicale wervelkolom. Bij patiënten die wel erosieve schade hebben 
aan de handen en voeten moet de reumatoloog erop alert zijn dat er ook schade 
aan de cervicale wervelkolom zou kunnen zijn, bijvoorbeeld wanneer anesthesie 
noodzakelijk is voor een operatie. 
 In Hoofdstuk 4 tot en met 6 hebben we een aantal behandelingsstrategieën 
onderzocht bij patiënten met langer bestaande RA, waarbij we gebruik hebben 
gemaakt van observationele data uit de Dutch RhEumatoid Arhritis Monitoring 
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(DREAM) registratie. Ondanks dat behandeling met biologicals, waaronder 
de tumor necrosis factor-α (TNF) -blokkers, effectief is gebleken in grote 
gerandomiseerde gecontroleerde studies, is er een groep patiënten bij wie deze 
middelen de ziekte onvoldoende onderdrukken. Als een patiënt onvoldoende 
effect heeft van een TNF-blokker bestaat er de mogelijkheid om de dosering 
op te hogen. Dit gaat echter gepaard met een grotere kans op bijwerkingen en 
hogere kosten. In Hoofdstuk 4 beschrijven we de frequentie en de effectiviteit 
van het ophogen van de dosering van adalimumab, etanercept en infliximab bij 
patiënten met RA in de dagelijkse praktijk. De resultaten van deze studie laten 
zien dat de frequentie van dosisophoging het hoogst was bij infliximab en lager bij 
adalimumab en etanercept. De effectiviteit van het ophogen van de dosering was 
echter beperkt bij alle middelen. Ophogen van de dosering zou mogelijk zinvol 
kunnen zijn bij patiënten die helemaal geen effect hadden van de begindosering, 
maar ook bij deze patiënten bleef de ziekte matig actief na dosisophoging. 
 Als een eerste TNF-blokker niet effectief is gebleken ondanks eventueel ophogen 
van de dosering, kan het starten van een andere TNF-blokker effectief zijn. 
Dit komt mogelijk doordat de TNF-blokkers van elkaar verschillen wat betreft 
structuur en eigenschappen. De reden van stoppen zou kunnen samenhangen met 
het onderliggende mechanisme van falen op de eerste TNF-blokker, bijvoorbeeld 
het vormen van antistoffen of genetische variatie leidend tot ineffectiviteit. De 
reden van stoppen van het eerste middel zou dan mogelijk voorspellend kunnen 
zijn voor de effectiviteit van een tweede TNF-blokker. Hoofdstuk 5 beschrijft de 
resultaten van een studie met als doel te onderzoeken of de reden van stoppen 
van een eerste TNF-blokker invloed heeft op de effectiviteit van een tweede TNF-
blokker. We definieerden drie redenen voor het stoppen van TNF-blokkerende 
therapie: geen respons, verlies van respons en bijwerkingen. Deze beschrijvende 
studie laat zien dat het starten van een tweede TNF-blokker na falen van de eerste 
effectief kan zijn ongeacht de reden van stoppen van het eerste middel. De reden 
van stoppen van het eerste middel kan dus niet gebruikt worden om die patiënten 
te identificeren die mogelijk meer gebaat zijn bij het starten van een tweede TNF-
blokker.   
 Bij patiënten bij wie ook een tweede TNF-blokker niet effectief is, zijn twee 
mogelijke behandelopties: het starten van een derde TNF-blokker of het starten 
van een biological met een ander werkingsmechanisme, bijvoorbeeld rituximab 
(een monoclonaal antilichaam gericht tegen CD20 op B-cellen). Er zijn nog geen 
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gerandomiseerde gecontroleerde studies verricht waarbij het effect van deze 
middelen met elkaar werden vergeleken. In Hoofdstuk 6 hebben we een indirecte 
vergelijking gemaakt tussen de effectiviteit van een derde TNF-blokker en de 
effectiviteit van rituximab na falen op twee eerdere TNF-blokkers in de dagelijkse 
praktijk over een periode van 12 maanden. We zagen een grotere verbetering 
van ziekteactiviteit en een trend naar een grotere verbetering in functionaliteit 
bij patiënten die behandeld werden met rituximab. Deze resultaten lijken erop 
te wijzen dat een middel met een ander werkingsmechanisme, zoals rituximab, 
effectiever kan zijn dan een derde TNF-blokker na falen op twee eerdere TNF-
blokkers. Wel zagen we in deze studie bij de patiënten die rituximab kregen een 
kleine toename in ziekteactiviteit in de periode van 6 tot 12 maanden. Rituximab 
wordt gegeven als twee infusen met een tussenperiode van twee weken. Daarna 
wordt geadviseerd om de infusen te herhalen na ten minste 6 maanden wanneer 
de ziekteactiviteit weer toeneemt. Het is aan de reumatoloog om te beslissen wat 
dit moment is bij de individuele patiënt. Onze resultaten uit deze observationele 
studie zouden erop kunnen wijzen dat herbehandeling met rituximab eerder 
nodig is om de ziekteactiviteit zo laag mogelijk te houden. 
 Uit eerder onderzoek is gebleken dat slechts een beperkte groep patiënten met 
RA in de dagelijkse praktijk voldoet aan de criteria om deel te nemen aan grote 
gerandomiseerde gecontroleerde studies naar het effect van medicatie. Het is 
daarom lastig om de resultaten uit deze grote studies te vertalen naar de dagelijkse 
praktijk bij de individuele patiënt. De resultaten van observationele studies, 
zoals die beschreven in dit proefschrift, benaderen het effect en de uitkomst van 
behandeling van patiënten met langer bestaande RA in de dagelijkse praktijk 
veel beter. Hierdoor zijn observationele studies een belangrijke aanvulling op de 
gevonden resultaten in grote gerandomiseerde gecontroleerde studies en kunnen 
ze bijdragen bij het nemen van beslissingen in de behandeling van patiënten met 
langer bestaande RA in de dagelijkse praktijk. Daarnaast kunnen resultaten uit 
observationele studies gebruikt worden om nieuwe hypotheses te formuleren 
voor verder onderzoek.
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Marlies Blom, de auteur van dit proefschrift, werd geboren op 15 april 1980 te 
Ede. De middelbare school volgde ze aan Het Streek te Ede waar zij in 1998 het 
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Na 8 jaar is het dan eindelijk zo ver dat dit boekje voor jullie ligt. Gedurende 
die jaren zijn er veel veranderingen geweest zowel wat betreft werk als privé. Er 
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lukken om al die mensen te bedanken, maar ik ga toch een poging wagen. 
 Allereerst wil ik mijn promotor en copromotor bedanken. Piet, jij hebt mij 
de mogelijkheid geboden om promotie-onderzoek te doen op de afdeling 
Reumatologie. Ik wil je vooral bedanken voor het geduld dat je met me hebt 
gehad en dat je me toch zo ver hebt gekregen om dit onderzoek af te ronden. Zelfs 
ondanks dat ik inmiddels een andere richting heb gekozen voor mijn carrière. 
Wietske, jij kreeg het steeds weer voor elkaar om mij het overzicht over het geheel 
te laten zien en me te motiveren om door te gaan. Allebei bedankt voor de zeer 
leerzame en fijne tijd.
 Verder wil ik Pilar bedanken voor de begeleiding bij mijn onderzoek naar 
rituximab. Helaas zijn niet alle studies die we bedacht hebben van de grond 
gekomen, maar het is wel leerzaam geweest. Ook heel erg bedankt voor de 
kritische blik die je hebt geleverd op de inhoud van dit boekje. 
 Marjonne, dank je wel voor je begeleiding bij het onderzoek naar de cervicale 
wervelkolom. We hebben heel wat uurtjes in het donker zitten turen naar 
röntgenfoto’s. Zelfs zo lang dat ik in zwart-wit ging dromen. Ik heb veel geleerd 
van je als supervisor bij de trials en in de polikliniek.
 Sjoukje, Franka, Mariëlle en Aggie: ik heb een heel leuke tijd gehad met jullie bij 
het trialbureau. Vooral de gezellige reisjes naar het buitenland zal ik niet vergeten. 
Wanneer gaan we weer borrelen?
 Ik wil al mijn collega-onderzoekers met wie ik ooit de Buitenhoek heb gedeeld 
of heb samengewerkt, Bea, Delia, Dewy, Jaap, Lydia, Laura, Madelon, Jos, Kavish, 
Calin, Paco, Mark, Twan, Marcel en Tim, bedanken voor de gezelligheid gedurende 
die jaren. Veel succes allemaal met alles wat op jullie pad komt! 
 Dit boekje zou er zeker niet zijn geweest zonder de hulp van de reumaconsu-
lenten, Ellis, Jacqueline, Carine en Joke. Verder mag ik Thea, Lia, Carien, Nicolette, 
Monique en Marjon van het datacentrum en Renske, Lieke, Tamara en Mieke 
van het secretariaat niet vergeten. Bedankt voor jullie ondersteuning bij mijn 
onderzoek! Daarnaast wil ik alle collega's van de Reumatologie die ik nog niet 
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heb genoemd ook bedanken voor de fijne jaren die ik  bij julllie op de afdeling heb 
gehad.
 Verder wil ik alle medewerkers, reumatologen en verpleegkundigen, van de 
andere ziekenhuizen die deelnemen aan de DREAM studie bedanken voor de 
inspanningen die ze geleverd hebben om de data te verzamelen die is gebruikt 
voor dit onderzoek. Ook wil ik alle patiënten bedanken die iedere keer weer 
bereid waren om vragenlijsten in te vullen en bloed af te staan. 
 Sinds mijn overstap naar de opleiding tot reumatoloog en later de 
ouderengeneeskunde heb ik op meerdere plekken gewerkt. Al mijn (oud-)
collega’s van het Rijnstate in Arnhem, De Waalboog in Nijmegen, de Praktijk 
Ouderengeneeskunde in Velp en GGnet in Zevenaar: bedankt voor de leuke en 
leerzame tijd die ik bij jullie heb en heb gehad. Het heeft even geduurd, maar dat 
beloofde feestje is er eindelijk!
 Ik zou ook nooit zover zijn gekomen zonder de leuke en ontspannen momenten 
met mijn vriendinnen van de studie: Esther, Nouchka, Judith, Marjolein, Nieke, 
Eefke, Esther, Iris, Renate en Wendy. Ook de uitjes en het shoppen met Nathalie 
en Maaike waren een welkome afleiding tussendoor om even weer op adem te 
komen. En ik mag Wendy, Inge en Christianne niet vergeten. Erg leuk dat we na 
al die jaren nog steeds contact hebben! Daarnaast wil ik mijn kwartetgenoten, 
Marieke, José en Silke, bedanken voor de gezellige muzikale avonden. 
 Natuurlijk wil ik ook mijn paranimfen bedanken. Broertje (al ben je inmiddels 
flink gegroeid en ook bijna doctor), dank je wel dat je mijn paranimf wil zijn. 
Geeft een goed gevoel om een man in pak naast me te hebben staan. Heel veel 
succes met jouw laatste loodjes. Ellen, onze vriendschap betekent veel voor mij. 
Het is voor jou nu ook een spannende tijd. Ik hoop dat het lukt om op deze dag 
naast me te staan. Ik wens jou en Jeroen heel veel geluk! Mocht je dan toch om wat 
voor reden dan ook er niet bij zijn dan neemt Janneke het van je over. Janneke, jij 
bent mijn ‘oudste’ vriendin en onze vriendschap voelt als vanzelfsprekend, maar 
is eigenlijk heel bijzonder.
 Paps en mams, ik wil jullie heel erg bedanken dat jullie mij hebben gesteund bij 
alle keuzes die ik tot nu toe heb gemaakt. Jullie staan altijd voor mij klaar: met een 
luisterend oor, maar ook met praktische hulp. Jammer genoeg zal ik vanaf nu wel 
weer zelf moeten poetsen. 
 Ik mag natuurlijk mijn schoonfamilie, Elise en de familie Denissen: Toos, 
Jos, Ellen, Vincent en Iris, niet vergeten. Je moet maar afwachten wie je als 
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Chapter 11
schoonfamilie erbij krijgt, maar ik heb met jullie geboft! 
 Lieve Harm, jou ontmoeten is het beste dat me is overkomen in de afgelopen 
jaren. Zonder jou was dit boekje zeker nog lang niet klaar geweest. Als ik weer 
eens in de stress schoot, heb je me iedere keer weer met mijn beide benen op de 
grond gekregen. Ik hoop dat we samen een hele mooie toekomst mogen hebben! 
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